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ABSTRACT 
 
4-Substituted pyrido[1,2-e]purines  (Figure 1) as anticancer agents have the ability to 
intercalate with DNA molecules and display improved cytotoxic activities especially towards 
the resistant cancer cell lines (MCF7R).
1-5
 These compounds were originally synthesized from 
imidazopyridines via poor yielding synthetic routes.
1 
Herein we discuss the development of 
more efficient strategies towards pyrido[1,2-e]purines. 
Since pyrido[1,2-e]purines vary mostly by their 4-substituent,
1-5
 we also wanted to develop 
more efficient strategy where the 4-substituent can be introduced in the last step (Figure 1). 
 
 
Figure 1. 4-Substituted pyrido[1,2-e]purines as anticancer agents.
1-5
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ABBREVIATIONS  
 
Ac                       Acetyl  
Ar                       Aryl  
Bu                       Butyl 
BuLi                   Butyllithium  
COSY                 Correlation spectroscopy (NMR) 
DCE                    Dichloroethane 
DCM                   Dichloromethane  
DEAD                 Diethyl azodicarboxylate  
DMA                   Dimethylacetamide  
DMF                   N,N-dimethylformamide  
DNA                    Deoxyribonucleic acid  
EI                        Electron impact (MS)  
EDG                    Electron donating group  
ESI                      Electronsprayionisation (MS)  
EtOAc                 Ethyl acetate  
EtOH                  Ethanol  
EWG                  Electron withdrawing group  
HMBC                Heteronuclear Multiple Bond Coherence  
HMQC               Heteronuclear Multiple Quantum Coherence  
HRMS                High Resolution Mass Spectra  
HSQC                 Heteronuclear Single Quantum Correlation (NMR) 
IUPAC                International union of pure and applied chemistry 
J                          Coupling constant (NMR)  
LDA                    Lithium diisopropylamide  
5 
 
MD                      Molecular dynamics calculation 
MDR                   Multi drug resistant (cancer cell lines) 
Me                       Methyl 
MeOH                 Methanol 
MS                      Mass Spectrometry  
n.d.                     Not determined  
N3Et                   Triethyl amine 
NMR                  Nuclear magnetic resonance spectroscopy 
NOE                   Nuclear Overhauser Effect (NMR)  
NOESY              Nuclear Overhauser Effect Spectroscopy (NMR)  
Ph                       Phenyl 
ppm                    Parts per million  
R                         Hydrocarbon 
RNA                   Ribonucleic acid  
rt                        Room temperature 
SAR                    Structure activity relationship 
SNAr                  Nucleophillic Aromatic Substitution 
t-BuOk               Potassium-tert-butoxide        
TBAF                 Tetra-n-butylammonium fluoride  
THF                   Tetrahydrofuran  
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1.  Aim of the project 
 
Synthesis of cytotoxic pyrido[1,2-e]purines was done before in literature through long poor 
yielding synthetic route starting with imidazopyridines (Scheme 1).
1
  
 
 
 
 
Scheme 1. Previous synthesis of pyrido[1,2-e]purines.
1 
 
Therefore, the aim of our project is to develop more efficient strategy towards the 4-
substituted pyrido[1,2-e]purines starting from the commercially available 6-chloropurine 
depending mainly on N-allylation of purines and C-8 functioanlzation towards RCM reactions 
(Scheme 2). 
 
 
 
Scheme 2. The synthetic strategy of the project towards pyrido[1,2-e]purines. 
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2. Introduction 
  
2.1 General  
 
Purines 3 are heterocyclic aromatic compounds, consisting of a pyrimidine ring 1 fused to an 
imidazole ring 2 (Figure 2).
6
 The name purine originates from the Latin word purum (pure) 
and uricum (urine). The name of this heterocycle was given by Emil Fischer as it was first 
synthesized from uric acid.
7
  
Owing to their large abundance in natural products and biomolecules, the purine scaffold has 
received an enormous interest among biologists and chemists. The most important purine 
containing biomacromolecules are DNA and RNA. 
 
 
 
Figure 2. Numbering system for pyrimidine, imidazole, purine, and pyrido[1,2-e]purine. 
 
While pyrido[1,2-e]purines 4 are consisted of the purine ring system fused to a benzene ring 
(Figure 2).  
Several pyrido[1,2-e]purines are reported to exhibit inhibitory activity against certain cancer 
cell lines including activity against multi-drug resistant (MDR) cell lines.
1-5
 
 
2.2 Biological significance of pyrido[1,2-e]purines. 
In aggressive tumors, the nuclear DNA of malignant cells often replicates more quickly than 
the nuclear DNA of surrounding healthy tissues.
8
 Interference in DNA replication of 
malignant cells inhibits tumor expansion, and reduces tumor mass if unsuccessful replication 
induces tumor cell death.
9
 A substantial fraction of effective anticancer drugs bind nuclear 
DNA, either covalently or noncovalently, and interfere with replication.
10
 The most prominent 
examples in general clinical use are the anthracycline antibiotics adriamycin and daunomycin, 
the anthracenedione mitoxandrone, and the antileukemic 9-anilinoacridineamsacrine.
11 
However, both the development of acquired resistance and the severity of toxicity associated 
with antineoplasic agents have necessitated the continuing development of new drugs. 
11 
 
4-Subistituted pyrido[1,2-e]purines have been studied to show cytotoxic activity towards 
human certain cancer cell lines. The ability of the ring system of pyrido[1,2-e]purines to 
intercalate with synthetic oligonucleotides has established their antineoplastic activities.
1-5
 
Cancer cells can develop mechanisms of resistance allows them to evade chemotherapy. The 
mechanisms of drug resistance are multifactorial: multidrug resistance (MDR) is the best 
known of all, since its molecular and genetic support has been identified.
12 
MDR is associated 
with the expression of a membrane P-glycoprotein (PGP) which is an energy dependent efflux 
pump responsible for reducing intracellular drug concentration in resistant cells.
13,14  
The pyrido[1,2-e]purines were found to be active against MDR cell lines, MCF7R, which 
were shown to have increased resistance to doxorubicin. Consequently, drug activity is not 
affected by MDR resistance.  
Therefore, in comparison with doxorubicin as anti-cancer drug, the cytotoxic activities of 
compounds 5, 6, 7, and 8 (Figure 3) were investigated against the breast cancer cell lines 
MCF7 and the resistant MCF7R in vitro which showed a range of sensitivities towards them.
1 
 
 
Figure 3. 
 
The concentration inducing 50% inhibition of cell proliferation (IC50) for doxorubicin was 7.5 
x 10
-7
 M for the parental cell line MCF7 and 5 x 10
-5
 for the MCF7R cells. Therefore, 
MCF7R cell line was more resistant to doxorubicin than parental MCF7cells. 
On the other hand, all breast cancer cell lines showed low growth activity when treated with 
median concentrations of compounds 5, 6, 7, and 8. The IC50 values for the sensitive parental 
cell lines MCF7 and the resistant cell lines MCF7R are illustrated in Table 1. 
 
12 
 
Table 1. IC50 values of the investigated compounds. 
  
The pyrido[1,2-e]purines reported here showed low activity on MCF7 parental cell lines, and 
interesting activity on MCF7R cell lines which proved to have increased resistance to 
doxorubicin.  
Furthermore, alternating the 4-substiuent with other functional groups were attempted to 
increase the bioavailability of the drug candidates. Anticancer compounds 10 and 11 (Figure 
4) were synthesized from compound 9 in order to, first, enhance biodisponibility by 
increasing the overall solubility in water, and second, enhance intercalating prosperities. To 
meet the first criterion, obtaining amphiphilic properties to enable these compounds to reach 
the intracellular target (i.e. DNA) by membrane transport, side chains of different lengths 
were used, providing different partition coefficients (1.3 (10)) and (2.38 (11)).
2
 
 
 
Figure 4. 
According to 
1
H, 
31
P NMR, and molecular dynamics calculations (MD), the most 
hydrophobic compound 11, exhibited only superficial interactions with the bilayers membrane 
due to micelle formation. While compound 10 could incorporate the external layer of the 
membrane and was more active in vitro against tumoral stems MCF7. 
13 
 
The two derivatives interacted quite differently with synthetic oligodeoxy nucleotide 
d(CGATCG)2. Compound 11 exhibited weak intercalations with d(CGATCG)2, only 
evocative of an external binding at the level of the G1C6 bases and is weakly mutagenic. 
Therefore, compound 11 does not fulfill the requirements for a drug with good anticancer 
activity. On the other hand, the interactions of compound 10 with DNA were quite different. 
A stable interaction of compound 10 in between the CG bases of the DNA fragment was 
observed. Thus compound 10 had proved to possess good intercalating properties and 
increasing interactions. 
Moreover, the three pyrido[1,2-e]purines 12, 13 , and 14 (Figure 4) of increasing 
hydrophilicity have been synthesized from 4-chloropyrido[1,2-e]purine 9 to be assessed as 
anticancer agents.
4
 These drugs interact quite differently with a synthetic 
oligodeoxynucleotide d(CGATCG)2. Compound 12 was very hydrophobic due to a phenyl 
residue in its side chain. Thus, it only showed limited interactions with the DNA minihelix 
without any evidence of intercalation. Compounds 13 and 14, on the other hand, have one 13 
or two 14 hydroxyl groups in their acyl chain and presented rather amphiphilic properties. The 
result was a similar intercalation of these derivatives (13 and 14) between C and G base pairs 
as revealed by intermolecular NOESY, 
1
H, and 
31
P chemical shift variations. 
In order to resolve the structure of the complex formed between d(CGATCG)2 and 
pyrido[1,2-e]purine dirivatives, 2-(pyrido[1,2-e]purin-4-yl)amino-ethanol 15 (Figure 5), a 
new antitumor drug under design, has been resolved using NMR spectroscopy and restrained 
molecular dynamic simulations.
5
  
 
 
Figure 5. 
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Intercalation conformation of compound 15 and DNA showed that the aromatic moiety of the 
drug molecule 15 was weakly intercalated between the external GC base pairs (Figure 6), with 
the side chain of compound 15 lying in the minor groove of the hexamer. However, the 
drug/DNA affinity is enhanced by a hydrogen bond between the terminal hydroxyl group of 
the end of the intercalant side chain and the amide group of guanine G6. 
 
 
Figure 6.
5
 Binding mode of the 2:1 complex of compound 15 with d(CGATCG)2 represented by the 
closest structure of the NMR ensemble. View looking from the intercalation site into the minor groove 
of the oligomer. The bases labeled with an asterisk belong to one strand of DNA; the bases labeled 
without an asterisk belong to the complementary strand. 
 
The preferential stacking of the pyridopurine derivative 15 on base G6 is stabilized by two 
alternative hydrogen bonding interactions (Figure 7). In most of the structures (38 out of 44), 
a hydrogen bond is possible between the extremity of the drug side chain (oxygen O13) and 
guanine G6 (amide proton H21 and nitrogen N2) (Figure 7A). The other hydrogen bond found 
in the second intercalation model involves the hydrogen H13, the oxygen O13 of the 
extremity of the drug side chain, and the nitrogen N3 of the guanine G6 (Figure 7B).  
Of the two interaction models studied, only one model (Figure 7A), yielded a stable insertion 
of compound 15 inside DNA. While, hydrogen bond involving H13 and O13 of the extremity 
of the drug side chain and nitrogen N3 of guanine G6 appears far less stable (Figure 7B). 
15 
 
 
Figure 7.
5
 Drug-base (G6) stacking interaction in the intercalation site. On the top is displayed the H-
bond observed in 38 out of 44 intercalation structures. On the bottom is displayed the H-bond 
observed in 6 out of 44 intercalation structures. 
 
Ab initio molecular simulation performed on the drug alone in a vacuum showed that the 
structure of compound 15 with minimum energy is planar up to carbon C11 of the tail. This 
structure is stabilized by a H-bond between H13 and N5. Ab initio optimized structures for 
both the lowest and second lowest energy structures show this same possibility of H-bond 
formation (Figure 8). 
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Figure 8. 
5 
Ab initio optimized structures of compound 15 in a vacuum. The lowest energy structure is 
displayed on the top of the figure. The second lowest energy structure is displayed on the bottom of 
the figure. Intramolecular H-bonds are displayed with dashed lines. 
A normal view to the helix axis and looking into the minor groove of d(CGATCG)2 of a 
representative structure of the NMR ensemble is presented in Figure 9A, and a view looking 
down the helix axis of the oligomer at the intercalation site is shown in Figure 9B. It can be 
seen that the pyridopurine derivative rings are not exactly perpendicular to the helix axis, with 
the drug stacking between the guanine G2 of one strand of the duplex and the guanine G6 of 
the other strand. The drug is not completely buried in the helical stack, but the stacking 
interaction seems to concern mainly the external ring of the drug comprising protons H6, H7, 
H8, and H9. 
 
Figure 9. 
5 
Top view looking into the minor groove and normal to the helix axis of d(CGATCG)2 at the 
intercalation site. Bottom view looking down the helix axis of d(CGATCG)2 of a representative structure of 
the NMR structure ensemble. The bases labeled with an asterisk belong to one strand of DNA; the bases 
labeled without an asterisk belong to the complementary strand. 
17 
 
2.3 N-alkylation of purines 
 
The significance of N-alkylation of purine core is not only about the biological impact, but 
also about advantages of removing or masking the acidic N-H proton in the synthetic routes. 
Many factors affecting the position of the introduced alkyl group whether to be at N-9, N-7, 
or N-3 position, from which, the substituent in the C-6 position,
15
 the used solvent,
16 
and the 
concentration of the reaction mixture.
17
  
 
2.3.1 Base-induced reaction 
 
Base-induced reaction is the most conventional and well-recognized method for N-alkylation 
of purines. A general mechanism illustrating the role of the base and alkyl halide in the N-
alkylation (Scheme 3).
18 
 
 
Scheme 3. General mechanism of base-induced N-alkylation of purines. 
Several methods were reported for purines base-induced N-alkylation using different solvents, 
bases, temperatures, and reaction times. For example, N-methylation of 6-chloropurine 16 
was done via four methods to obtain N-9 and N-7 isomers (Scheme 4). Using NaH as a base 
in method A requires neutralization at the end of the reaction. The main disadvantage of 
method B and C is the difficult elimination of the used solvent (DMSO) due to its high 
boiling point (190 °C). Heating is used in method C to accelerate the reaction and 
consequently decreasing the reaction time to 30 min than the usual time (16 - 24 h), but this 
required doing the reaction in a sealed tube. On the other hand, Method D was the most 
practical method due to its simplicity, ease of removal of DMF (boiling point = 150 °C), and 
the high yields where products 17 and 18 were isolated in yields 78% and 19% respectively.   
18 
 
 
Scheme 4. Reactions and conditions: (A) NaH, MeI, DMF, rt, 16h;
19
 (B) K2CO3, MeI, 
DMSO, rt, 24 h;
20
 (C) K2CO3, MeI, DMSO, sealed tube, 55ºC, 30 min.
21 
(D) K2CO3, MeI, 
DMF, rt, 16h.
21 
Method D which is commonly used, was employed for N-allylation of 6-chloropurine 16 by 
allyl bromide in the presence of K2CO3 as a base in DMF. N-9 and N-7 allylated isomers were 
obtained in a ratio (2.7:1) and isolated in yields 59% and 20% respectively (Scheme 5).
22 
 
 
Scheme 5. 
 
In order to examine the influence of the C-6 substituent on the resulting ratios between N-9 
and N-7 alkylated compounds, alkylation using the same conditions for the base and solvent 
for compounds 21 a-k employing various substituents on the 6-position was done (Scheme 
6).
15
  
The results were indicating that the obtained ratios between the N-9 and N-7 isomers are not 
attributed to the steric bulk or the electronic effect of 6-substituent on the purine ring. Further 
studies concluded that it is related to the partition coefficient (lipophilicity) parameter () of 
the introduced substituent. The relation between the lipophilicity of the 6-subsitiuent and 
tendency towards formation of N-9 isomer is directly proportional (Scheme 6).
15
   
  
19 
 
 
Scheme 6. 
 
On the other hand, allylation of compound 24 in the same conditions, gave the 9-allylpurine 
derivative 25 (35%) and the corresponding 3-allylpurine derivative 26 (58%) (Scheme 7).
23
 
The ratio of the allylated products 25 and 26 was analogous to the benzylated products 
prepared from 8-bromoadenine previousely.
24 
 
 
 
Scheme 7. 
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2.3.2 Mitsunobu reaction 
A general protocol for N-alkylation of the 6-chloropurines by Mitsunobu reaction has been 
developed depending on functionalization of a range of various alcohols and 
diethylazodicarboxylate (DEAD).
25,26 
The mechanism of Mitsunobu reaction
18
 involves a nucleophilic attack of the 
triphenylphosphine on DEAD to generate a phosphonium intermediate that binds to the 
alcohol oxygen, activating it as a leaving group. Substitution by the 9-purinyl anion completes 
the process (Scheme 8). 
 
 
Scheme 8. General mechanism of the Mitsunobu reaction on purines. 
Applying the Mitsunobu reaction on 6-chloropurine 16 using ethanol or benzyl alcohol has 
led to higher selectivity, compared to base-induced method, in favor of N-9 isomer (27a or 
27b) as the major product (yields 81%, 71%, respectively), while N-7 isomer (28a or 28b) is 
21 
 
formed as the minor product (yields 14%, 25%, respectively) (Scheme 9).
26 
The challenge in 
this kind of reactions is separating the desired products from triphenylphosphine oxide or 
bis(ethoxycarbonyl) hydrazine which makes it inconvenient for large scale syntheses. 
 
 
Scheme 9. 
 
2.3.3 Phase-transfer catalysis 
 
Aliquat 336 and TBAF are quaternary ammonium salts that are effectively employed in 
phase-transfer catalyzed alkylation. Compared to base-induced and Mitsunobu reactions, the 
major advantages of N-alkylation of 6-substitueted purines via phase-transfer catalysis are the 
short reaction time, simple work up, high yields, and the favourable substitution at N-9 
position.
27 
An approach for a facilitated alkylation of pyrimidines and purines by TBAF was achieved 
for a short reaction time (1 h) giving high yields (85-99%). For instance, N9-methylation of 
adenine 29 gave an excellent yield (95%) of compound 30 (Scheme 10).
28 
 
 
Scheme 10. 
22 
 
2.4 Amination of 6-halopurines 
Amination of 6-halopurines usually go through nucleophilic aromatic substitution via 
addition-elimination mechanism where the electron withdrawing halide attached to the 
aromatic skeleton activates the ring towards nucleophilic attack. The loss of the halide comes 
fast because the ring becomes aromatic again. A proposed mechanism of amination of purines 
is illustrated in Scheme 11.
16
 
 
 
 
Scheme 11. 
 
2.4.1 Heat-induced nucleophilic substitution 
 
 
Reaction enhanced by heating is the most conventional method for amination of 6-halopurines 
and it is commonly used (Scheme 12 and Table 2).
29-31 
 
 
 
Scheme 12. 
23 
 
Table 2. Amination of 6-chloropurine derivatives with various amines. 
 
 
The adenine derivatives 33 and 34 were prepared
 
by amination of compound 19 with 
piperidine 31 or morpholine 32 at 100 °C in H2O. The conventional amination method of 
piperidinyl and morpholinyl derivatives 33 and 34 by refluxing in water gave good yields 
(95% and 91%, respectively) (Scheme 13).
32 
 
 
 
Schem 13. Reagents and conditions: H2O, reflux, 24 h. 
 
In case of simple 6-(piperidin-1-yl)purine analogues 35-38 which are lacking substituents in 
N-9 position, they were prepared by direct nucleophilic substitution of 6-chloropurine 16 
using triethyl amine as a base and n-BuOH as a solvent instead of water due to the low 
polarity of N-9 unsubstituted purines and consequently the poor solubility in water even in the 
presence of the highly basic piperidine in the reaction (Scheme 14).
33 
24 
 
 
Scheme 14. Reagents and conditions: 4-substituted piperidine, Et3N, n-BuOH, 100 °C 
 
 
2.4.2 Microwave-promoted nucleophilic substitution 
 
Microwave irradiation as a non-conventional energy source is a useful technique in organic 
chemistry. Many reactions have been demonstrated to result in higher yield and reduced 
reaction time under microwave irradiation compared with using the conventional heating 
method.
32-34
 
Microwave promoting nucleophilic substitution reaction between a number of 6-chloropurine 
derivatives with piperidine, pyrrolidine, or hexamethyleneamine in water were employed 
(Scheme 15).
34
 
This method has several advantages such as mild reaction conditions and short reaction times. 
Furthermore, most of the reactions involved are efficient, giving the desired compounds in 
higher purity and yield. 
 
25 
 
 
Scheme 15. Nucleophilic substitution reaction of 6-chlororopurines derivatives with 
piperidine, pyrrolidine or hexamethyleneamine.
34
 
 
The products from 2,6-dichloropurine were obtained in higher yields compared with those 
from other 6-chloropurine analogues under the same reaction conditions. Moreover, when R
2
 
was cyanoethyl or allyl, the yields were higher compared with other substituted substrates. 
Using acyclovir analogue 39 as a substrate, a variety of nucleophilic aromatic substitutions 
were carried out using different amines as nucleophiles (Table 3).
35 
Yields and reaction times 
under conventional conditions and under microwave irradiation were compared (Table 3). 
The standard protocol for microwave-assisted reactions involved 1.1 eq of the corresponding 
amine, 1.1 eq of diisopropylethylamine (DIPEA) and ethanol as the solvent (conditions A).  
Alternatively, the reactions were carried out under conventional heating in an oil bath 
applying established conditions (conditions B and C) for nucleophilic aminations.
36
 The 
microwave assisted reactions proceeded in all cases with higher yields (72% - 83%), and 
nearly complete conversions were already observed after short reaction times (10 min). In 
contrast, much longer reaction times (16 h) were needed to achieve satisfying conversions 
under the common conditions (conventional heating), which also led to generally lower yields 
(58% - 75%) (Scheme 16 and Table 3). 
 
Scheme 16. Amination of acyclovir analogue. 
26 
 
Table 3. Amination of acyclovir analouge 39 with various amines.
35
 
 
Conditions A: 1.1 eq. amine, 1.1 eq. DIPEA, EtOH, microwave (120 °C, 150 W), 10 min. 
Conditions B: 1.1 eq. amine, 1.1 eq. DIPEA, BuOH, 75 °C, 16 h.  
Conditions C: 5 eq. amine, EtOH, 75 °C, 16 h. 
 
2.5    C-8 Halogenation of purines. 
 
2.5.1 Direct Halogenation of 6-aminopurines. 
 
Applying direct bromination on N-unsubstituted purines in order to obtain C-8 brominated 
purine derivatives was achieved smoothly using molecular bromine or NBS through several 
methods.
29,37,38 
The direct bromination of C-8 position of adenine 29 using Br2 has been reported frequently 
giving 8-bromoadenine 41 in a high yield with various ways. Methods a,
29
 b,
37
 or c
37
 led to 
70% yield while method d
38
 led to 83% yield (Scheme 17). 
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Scheme 17. Reagents and conditions: (a) Br2, DMF, r.t., overnight;
29
 (b) Br2, DMF, 70 ºC, 2 
h;
37
 (c) Br2, r.t., overnight;
37
 (d) Br2, H2O, r.t., overnight.
38 
 
On the other hand, by replacing the NH2 group in adenine with a heterocyclic amine, the 
direct bromination of C-8 position was accomplished using the liquid bromine in a buffer 
solution of acetic acid and sodium acetate giving high yields (Scheme 18).
23 
 
 
Scheme 18. 
 
2.5.2 Lithiation / halogenation reactions. 
Lithium diisopropylamide (LDA) is generated by reacting diisopropylamine with n-BuLi in 
THF at -78 °C under inert atmosphere (Scheme 19).
39
  
LDA has proton-removing ability as a strong base but without any further functions like 
involving in a nucleophilic substitution due to its steric bulk which allows portons to be 
28 
 
attached to the basic nitrogen atom and preventing alkyl groups from doing so, thus it was 
termed as a non-nucleophilic base. It is a strong base commonly used for deprotonating the 
weakly acidic proton, H-8, in purines. 
 
 
Scheme 19. Mechanism of formation of LDA 
The reason behind using LDA for such reactions instead of other strong bases like hydroxides 
e.g. NaOH, KOH, is that such bases involve in a nucleophilic substitution reaction instead of 
deprotonation, displacing any good leaving group attached to the purine core to give the 
hydrolysed compounds.
40  
Furthermore, LDA is favoured over alkyllithiums such as n-BuLi and t-BuLi since they 
potentially participate in halogen exchange for attached halogens instead of deprotonation.
41
 
C-8 lithiation of purines is done using LDA as a strong base to deprotonate C-8 position of 
purines to trap the 8-purinyl anion which attacks the elctrophile that acts as a halogen donor, 
in the haolgenation step afterwards, as illustrated in the mechanism (Scheme 20). This usually 
results in good yields.
42-53 
 
Scheme 20. General mechanism for lithiation-halogenation reactions. 
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A variety of different electrophilic sources can be utilized for the C-8 halogenation.
8,10
 
Molecular bromine, 1,2-dibromotetrachloroethane, or cyanogenbromide are used as bromine 
donors. Iodination can be done via molecular iodine. Besides, hexachloroethane is a good 
source for chlorine. 
Effectively, C-8 position of 6-subistituted, 9-alkylated purines can be halogenated easily, in 
most cases, by applying lithiation followed by halogenation upon many derivatives of purine 
compounds which contain different substituents in 6- or 9-position using different 
electrophiles. That is usually achieved smoothly giving yields from moderate to high as 
illustrated (Scheme 21 and Table 4).
21,37,43,54 
 
 
Scheme 21. (a) Reagents and conditions (see Table 4) 
 
Table 4. Lithiation-halogenation of purines. 
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2.6 Organomagnesium addition reactions on purines. 
Allylmagnesium bromide reacts with 2,6-dihalopurine 55 giving derivatives 56 and 57 
(Scheme 22).
55
  
As a result of the addition of Grignard reagent to the 8-position of the purine nuclei, 2-
magnesiated purine 57 is formed, which is stable and does not rearrange to the 8-derivative 
due to the presence of electron-donating substituents in the 6-position of purine nuclei. 
Smooth coupling of Grignard reagents with compound 55 is probably a result of the activation 
of iodine by the chlorine atom at the 2-position of the purine nuclei. 
 
 
Scheme 22. 
Stable adducts are formed when 1,3-, 1,7-, and 3,7-dibenzylpurin-2-one react with Grignard 
reagents and the reactions take place in the purine 6- or 8-position.
56
 
When the 6-phenylpurinone 58 was treated with ethylmagnesium bromide, addition took 
place in only the 8-position to afford 8-ethyl adduct 59 which was oxidized during flash 
chromatography on silica gel to compound 60 (Scheme 23).This reaction demonstrates the 
large reactivity differences among dibenzylated purinones. 
 
 
 
Scheme 23. 
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1,7-Dibenzyl-6-phenyl-2-purinone 61 reacted with ethylmagnesium bromide to afford 8-ethyl 
adduct 62 as the major product which was oxidized on silica gel during the chromatographic 
separation to compound 64. In spite of steric hindrance, some addition of the nucleophile to 
the 6-position also took place, and compound 63 was formed (Scheme 24).
56 
 
 
Scheme 24. 
 
When 3,7-dibenzylated 2-purinone 65 was reacted with ethylmagnesium bromide, addition 
happened preferentially to the 6-position to give compound 66 as the major product while the 
8-ethyl adduct 67 was formed as the minor isomer. The reaction gave a ca 7:2 mixture of the 
two regioisomers 66 and 67 (Scheme 25).
56
  
 
 
 
Scheme 25. 
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2.7  Organoindium addition reactions. 
Indium element was discovered by Ferdinand Reich and Hieronymous Theodor Richter in 
Freiberg, 1863. It was named for the indigo blue line and used in metal alloys and electronics. 
It has two oxidation states (I) and (III). 
The first example of an indium-mediated reaction was published by Rieke and co-worker in 
1975.
57
 To accomplish the reaction, they used especially activated indium metal prepared 
from indium chloride and potassium metal. This activated indium efficiently mediated the 
Reformatsky-type reaction of ethyl bromoacetate with carbonyl compounds (Scheme 26). 
 
 
 
Scheme 26. Indium-mediated Reformatsky-type reaction 
 
Since 1988 when Araki and Butsugan used indium for the Barbier-type addition of allyl 
bromide to carbonyl compounds (Scheme 27).
58 
Synthetic use of indium metal has attracted 
considerable attention and a number of indium-mediated reactions have been reported. 
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Scheme 27. Indium-mediated Barbier-type reaction. 
Although the reactive organoindium intermediate is still a matter of debate, recent studies 
have revealed a lot about it.
59
 After reacting indium metal with allyl bromide in THF, two 
major compounds were crystallized and separated to be identified as monoallylindium 
dibromide and diallylindium bromide (Scheme 28).
60  
In addition, other species may also be present in the solution, mass spectrometry has detected 
a variety of organoindium (III) species such as InRX
3-
, RXIn
+
, R2In
+
, X2In
+
, many of them are 
in equilibrium with each other.
61 
 
Scheme 28. 
 
Organoindium species adds to carbonyl compounds more or less in the same way as 
organomagnesium species (Grignard reagents).
62
 They also reacts with other functional 
groups
63,64
 including electron deficient heterocycles.
65,66
 
In fact, synthetic reactions in aqueous media evidence the advantages of indium reagents. For 
example, indium metal affects the allylation of aldehydes and ketones with allyl halides in 
water at room temperature without inert atmosphere (Scheme 29).
67 
 
 
Scheme 29. 
The reactions of allylindium reagents with C=N bond-containing compounds have been 
extensively investigated.
62,68
 The C=N bonds in heterocyclic compounds, such as, pyridine, 
34 
 
quinoline, isoquinoline, and azirine did not, however, react with allylindium reagents under 
normal conditions.  
Recently Hirashita and co-workers reported the reaction of allylindium reagents and azirines 
to produce allylaziridines in good yields (Scheme 30).
69
  
Azirines are known to have a highly strained ring similar to cyclopropenes and are expected 
to be reactive substrates. The delivery of the allyl groups was well regulated by the 
substituents at the C-3 carbon of azirines.  
The cis-allylation with respect to the substituent was realized with azirines bearing a 
hydroxymethyl or an acetoxymethyl group, due to the chelation with allylindium reagents, 
whereas, the trans-allylation was observed with azirines substituted by non-chelating groups, 
such as, methyl, phenyl, or ester groups owing to the steric repulsion. 
Scheme 30. 
Yoon and co-workers reported an indium-mediated allylation of quinoline and isoquinoline 
activated by phenyl chloroformate in THF at room temperature and obtained the allyl 
dihydroquinoline and allyl dihydroisoquinoline in good yields (Scheme 31).
65
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Scheme 31. Indium-mediated allylation of quinoline and isoquinoline activated by phenyl 
chloroformate.
65
 
2.8 Olefin metathesis 
 
The word Metathesis is derived from the Greek for “change position”. Olefin metathesis is a 
metal-catalyzed transformation which involves the exchange of groups around double bonds. 
It is promoted by a metal carbene complex which acts on carbon-carbon double bonds and 
rearranges them via cleavage and reassembly through series of reversible [2+2] cycloadditions 
and cycloreversions.
70-74 
According to the mechanism proposed by Chauvin,
75
 the coordination of an olefin to a metal 
carbene catalytic species leads to the reversible formation of a metallacyclobutane (Scheme 
32). This intermediate then proceeds by cycloreversion yielding an olefin that has exchanged 
a carbon with the catalyst’s alkylidene. 
 
 
Scheme 32. General mechanism of olefin metathesis. 
 
Several well-defined, single-species catalysts based on different transition metals such as 
titanium,
76
 tungsten,
77-79 
molybdenum,
77,80 
rhenium,
81
 osmium,
82
 and ruthenium
83-85 
have been 
evolved. The early transition metal catalysts are very active but also sensitive to many 
functional groups found in organic molecules, as well as moisture and air which significantly 
limits their synthetic applications. 
Focusing on ruthenium-based catalysts (Figure 10), high reactivity of 2
nd
 generation 
ruthenium catalysts, such as catalyst 69 and 70 enable them to react with electron-deficient 
-unsaturated carbonyls, which are inert to catalyst 68.86,87 
36 
 
 
Figure 10. 
 
While both catalysts 69 and 70 maintain excellent selectivity in most cases towards Z-
isomers
88
 for olefins typically of ruthenium catalysts, they have somewhat slower rates of 
initiation than the first generation catalysts. 
 
2.8.1 Ring opening metathesis polymerization (ROMP) 
 
Ring opening metathesis polymerization is a chain-growth type polymerization (Scheme 33) 
which relies on monomer ring strain and therefore, thermodynamically favored for strained 
ring systems, such as 3-, 4-, 8- and larger-membered compounds, thus, it can be efficiently 
controlled by catalyst loading.
89 
 
 
Scheme 33. 
 
Block copolymers can be made by sequential addition of different monomers (a consequence 
of the "living" nature of the polymerization). 
 
 
37 
 
2.8.2 Acyclic diene metathesis (ADMET) 
 
Acyclic diene metathesis is considered to be a step-growth
90
 polycondensation-type 
polymerization reaction, which makes strictly linear chains from unconjugated dienes 
(Scheme 34).
91-95
  
 
 
 
Scheme 34. 
 
ADMET demands a very high monomer conversion rates to produce polymer chains of 
considerable size. Therefore, the more active 2
nd
 generation catalysts such as 69 and 70 are 
usually better suited for ADMET than bisphosphine ones like catalyst 68 (Figure 10).
93 
 
2.8.3 Cross metathesis (CM) 
 
Olefin cross-metathesis
96
 can be described as the intermolecular mutual exchange of 
alkylidene (or carbene) fragments between two olefins promoted by metal-carbene complexes 
(Scheme 35). Thus, it is a convenient route to functionalized and higher olefins from simple 
alkene precursors. 
 
 
 
Scheme 35. 
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The major issues dominating cross metathesis process are the control of homodimerization of 
the resulting olefins in order to obtain useful yields. On the other hand, the ratios of E/Z which 
are hard to control and predict. 
 
2.8.4  Ring closing metathesis (RCM) 
 
Ring closing metathesis can be simply identified as an intramolecular metathesis of diene to 
form a cyclic olefin. The overall reaction mechanism involves a series of alternating [2+2] 
cycloadditions and cycloreversions between metal alkylidene and metallacyclobutane species 
(Scheme 36).
97 
 
 
 
Scheme 36. General mechanism of ring closing metathesis. 
 
By applying RCM on the 8,9-diallylpurine derivatives 71, 72, and 73 using Grubbs’ 2nd 
generation catalyst 69 (19 mol %) in DCM at room temperature for 2 days, this gave 6,9-
dihydropyrido[1,2-e]purine derivatives 74, 75, and 76 in high yields (Scheme 37).
23 
 
39 
 
 
Scheme 37. 
Another example for employing RCM on purine substrates, formation of an eight-membered 
ring on compounds 77a-d. In the synthesis of azacyclooctenes by RCM, the yield is usually 
affected by the N-substituent.
98,99  
Only with the presence of the bulky N-Boc-group in compound 77d, the reaction was carried 
out successfully either by Grubbs’s II catalyst to give moderate yield (54%) or by the 
bisphosphine-free complex, Hovedya-Grubbs’ II catalyst to give higher yield (73%) (Scheme 
38).
100 
 
Scheme 38. 
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2.9    Oxidation (re-aromatization) 
2.9.1 Oxidation of heterocyclic compounds via MnO2 
Selective oxidation for some functional groups in a molecule can be achieved via MnO
2 
at 
room temperature, but heat is also used.
101
 The oxidizing ability of MnO
2 
increases sharply 
above 70 °C usually with loss of selectivity.
102 
Manganese dioxide has the highest oxidizing 
activity in acidic media, moderate activity in neutral media, and close to zero activity in 
alkaline media.
103 
 
The main advantages of MnO2 are the availability, low price, and the acceptable (with rare 
exceptions) degree and selectivity of the transformations even at room temperature. 
Oxidation of substituents in heterocycles is a common benefit of MnO2, but as a rule methyl 
groups in five-membered heterocycles are not oxidized by MnO2.
104
 However, 3-formyl-2-
methyl-substituted 79a and 2-formyl-3-methyl-substituted 79b indoles are oxidized to the 
dialdehyde 80 on account evidently of the activating effect of the CHO group (Scheme 39).
104 
 
 
Scheme 39. 
A large, constantly increasing, number of examples of the use of MnO
2 
for the partial 
dehydrogenation or aromatization of heterocyclic compounds are known. Manganese dioxide 
is recognized as the most suitable dehydrogenizing agent for the synthesis of 2,4-di-
acylfurans
105 
and also N-benzyl- and N-acylpyrroles.
106,107 
Thus, N-acylpyrroles 82 were 
obtained from N-acylpyrrolines 81 with yields of 78-91% (Scheme 40).
107
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Scheme 40. 
 
An example for the convenience of using MnO2 as oxidising agent on purine derivatives, 
when the rearomatization of the adduct 83 was done via DDQ, the chromatographic 
separation of the polar purinone 58 and residual DDQH2 was tedious. Thus, compound 58 
was easily isolated in high yields when the adduct 83 was oxidized with MnO2 in a polar 
solvent, DMSO or dichloromethane (Scheme 41).
56 
 
 
 
Scheme 41. 
 
In the same way, compound 84 was easily oxidized to compound 85, when treated with 
activated MnO2 in dichloromethane (Scheme 42).
56 
 
 
Scheme 42. 
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2.9.2 Oxidation of heterocyclic compounds via DDQ 
Dichloro dicyano quinone (DDQ) has been investigated as a powerful oxidising agent for a 
wide range of reactions. DDQ reacts with water leading to possible hydrolysis of the cyanid-
ion.
108 
Stability is generally increased in acidic conditions and at low temperatures. DDQ might 
decompose at temperatures above 200 °C giving HCN vapors. DDQ is very soluble in THF 
and ethyl acetate, moderately soluble in dichloromethane, toluene, dioxane, acetic acid, and 
insoluble in water (but reacts with). 
It has been observed that the rate of the reaction with DDQ is accelerated in polar solvents 
and catalyzed by proton-donor species. The mechanism is supposed to be bimolecular. In the 
first rate-determining step, the formation of a charge-transfer complex occurs, according to 
the following scheme:
109
 
RH2 + QH
+ 
RH
+
 + QH2 , where Q : Quinone, R : reacting species, RH
+
 : charge-transfer 
complex. 
From the charge-transfer complex, two reactions are likely to happen: 
- Elimination of a proton to give an insaturation on the molecule 
- Wagner-Meerwein type rearrangement prior to the loss of proton may occur in 
specific cases. 
For some other special reactions, a radical mechanism may be involved. 
Dehydrogenation of hydrocarbons is based on an initial rate-determining transfer of hydride 
ion from the hydrocarbon to DDQ leading to hydroquinone derivative. The feasibility of the 
reaction depends upon the degree of stabilization of the transition-state carbocation. It has 
been observed that the presence of alkenes or aromatic moieties is sufficient to initiate 
hydrogen transfer in presence of DDQ, such as the synthesis of chromenes 87 by addition of 
an insaturation on chromanes
 
86
 
(Scheme 43).
110
 
 
Scheme 43. 
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The regioselective dehydrogenation of steroids allows aromatization of specific cycles in the 
whole skeleton towards successful synthesis of the target molecules (Scheme 44).
111
 
 
 
 
Scheme 44. 
 
The dehydrogenation of hydroaromatic heterocycles is a powerful way to rearomatize 
heterocycles after they were functionalized through a nucleophilic addition. 
 
For purine substrates, in many cases, DDQ is more advantageous over MnO2 for the 
rearomatization. Adducts 88a-d were oxidized smoothly by DDQ to give the compounds 89a-
d. Its chemical analogue Chloranil also afforded these oxidations, but on the other hand, 
activated MnO2 failed to oxidize the alkyl adducts 88c and 88d (Scheme 45 and Table 5).
56 
 
 
 
Scheme 45. 
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Table 5. Rearomatization of the adducts 88a-d by several oxidants.
56 
 
 
2.10 Overview of double-bond migration. 
 
It is well-observed through many literature reactions,
21,100,112-114
 that strong bases are affecting 
the terminal double bond of the allyl groups attached to the N-7 or N-9 in purines. That can be 
attributed to two factors, first, the ability of the strong base to deprotonate the allyl group and 
drive the migration, second, the tendency of the double bond to migrate towards the aromatic 
skeleton of purine forming a conjugated system which is more stable (Scheme 46).
21,112 
 
 
Scheme 46. General mechanism for base impact on N-allyl purines.  
 
Protons of the allyl group attached to the purine ring undergo deprotonation under the 
influence of organolithium reagents, but not usually organomagnesium reagents, since they 
are strong bases that possess pKa values higher than the allyl group (pKa ≃ 38, in case of 
45 
 
CH2=CH-CH2-H)
113
 which already decreased than normal due to linkage with the purine ring 
that lowers its basicity. 
Potassium carbonate was chosen to enhance a selective migration for the double bond in the 
diallylpurine 90. The reaction was done in refluxing acetonitrile to migrate the double bond in 
the N-7 allyl giving compound 91 in excellent yield (Scheme 47).
100 
In the case of compound 92, the reaction was slower and required refluxing in n-butanol 
instead of acetonitrile but after all, the reaction was not completely selective and 10% of 
isomer 94 was obtained (Scheme 47).
100 
 
 
 
Scheme 47. 
 
When both N-7 and N-9 allylated purines were subjected to bases such as K2CO3 or t-BuOk, 
rearrangement of the allyl group double bond occurred whether towards E- or Z-selectivity 
(Scheme 48).
114 
 
46 
 
 
 
Scheme 48. Reagents and conditions (a) K2CO3, MeCN, Δ; (b) t-BuOK, DMSO, rt. 
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3.  RESULTS AND DISCUSSION. 
 
 
 
 
Scheme 49. General summary of the project synthetic routes. 
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A general summary for the work done in the project and the selected synthetic routes is 
illustrated in Scheme 49. 
Two major routes were attempted towards the syntheses of the diallylpurines for RCM 
reactions. Route A involves mainly C-8 halogenation before N-allylation, while route B 
involves N-allylation before C-8 functionalization with other modifications introduced to 
improve this synthetic route which will be discussed in detail.  
3.1 Synthesis directed towards diallylpurines for RCM reactions (route A) 
The original route selected towards the syntheses of diallylpurines for RCM reactions 
involved C-8 bromiation followed by N-allylation as the key steps (Scheme 50). 
 
Scheme 50. Steps (a) C-6 amination, (b) C-8 bromination, (c) N-allylation, (d) C-8 allylation 
by Stille coupling. 
 
3.1.1 Synthesis of 6-(piperidin-1-yl)-9H-purine (35). 
6-(Piperidin-1-yl)-9H-purine 35 was prepared by direct nucleophilic substitution of 6-
chloropurine 16 following a literature procedure.
33 
Amination of 6-chloropurine 16 with piperdine at 100 °C for 15 h was done in n-BuOH, using 
triethyl amine to increase the basicity of reaction medium, and consequently the solubility of 
6-chloropurine (Scheme 51).  
 
Scheme 51. 
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According to the literature procedure,
33
 the crude product was triturated with MeOH once to 
give 56% yield but we succeeded to increase the yield significantly (87%) by triturating the 
crude product in MeOH three times. Moreover, the crude product did not require any further 
purification. 
 
3.1.2 Synthesis of 8-bromo-6-(piperidin-1-yl)-9H-purine (24). 
Bromination of compound 35 was reported previously in literature using bromine in a buffer 
solution of acetic acid and sodium acetate at 80 oC for 3 hours. After purification by flash 
chromatography the obtained yield was excellent (97%).
23 
Using solvents which are difficult to remove due to their high boiling points such as water is 
inconvenient. On the other hand, using the buffer solution demands chromatographic 
purification. Therefore, bromination of compound 35 was attempted to be improved using 
liquid bromine as a brominationg agent and solvent. The crude product was relatively pure, 
thus it only required to be washed with hot water, acetone, and diethyl ether to be purified 
more. Despite of the simplicity and convenience of this method, it afforded a lower yield 
(62%) (Scheme 52). 
 
 
 
Scheme 52. 
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3.1.3 Synthesis of 9-allyl-8-bromo-6-(piperidin-1-yl)-9H-purine (25) and 3-allyl-8-bromo-
6-(piperidin-1-yl)-3H-purine (26). 
 
Following a literature procedure for this reaction,
23
 8-bromo-6-(piperidin-1-yl)-9H-purine 24 
was N-allylated with allyl bromide in the presence of potassium carbonate and DMF as a 
solvent (Scheme 53). 
 
 
Scheme 53. 
 
The N-9 allylated isomer was formed as the minor product and the N-3 allylated isomer as the 
major one.  According to the 
1
H NMR spectrum of the crude product, the isomer distribution 
was (N9/N3) 1 : 2.8. The products 25 and 26 were isolated in 21% (Lit.
23
 35%) and 69% 
(Lit.
23
 58%) yields, respectively, by flash chromatography. 
The ratio of the allylated products 25 and 26 were analogous to the benzylated products 
prepared from 8-bromoadenine previously.
24
  
The regioselctivity of compound 24 towards the N-3 alkyation could be explained comparable 
to adenine. Selective N-9 alkylation of adenine was often seen when the reaction is performed 
in the presence of base.
21 
However, when 8-bromoadenine was N-alkylated under basic 
conditions, the selectivity towards N-9 was decreased and the 3-alkylated compound was 
obtained as the major isomer.
24
 Therefore, it could be concluded that the presence of the 
bromide in the C-8 position had directed this reaction towards the N-3 alkylation due to its 
steric bulk.    
The measured melting points for compounds 25 and 26 were 80-82 ºC and 111-113 ºC, 
respectively, while the reported ones in literature are 65-66 ºC and 82-83 ºC, respectively. 
This variation could be attributed to the less purity of the isolated products in our case. 
51 
 
HMBC NMR was employed to confirm the structure of compound 25. Diagnostic long-range 
couplings of N(9)CH2 with =CH2, CH=, C-8, and C-4 were observed to indicate to the correct 
position of the allyl group (Table 6). 
Table 6. Selected correlation from long range HMBC NMR spectrum for compound 25. 
X = coupling between carbon and proton 
 
 
On the other hand, HMBC NMR of compound 26 refers to long-range couplings of N(3)CH2 
with =CH2, CH=, C-2, and C-4 which indicates to the right position of the allyl group (Table 
7). 
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Table 7. Selected correlation from long range HMBC NMR spectrum for compound 26. 
X = coupling between carbon and proton 
 
 
Due to the low yield of 9-allyl-8-bromo-6-(piperidin-1-yl)-9H-purine 25 which is a key 
compound for further synthesis of the diallylpurine 71, this strategy was stopped and C-8 
allylation by Stille coupling was not performed. An alternative route (Chapter 3.2) was 
attempted.  
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3.2 Synthesis directed towards diallylpurines for RCM reactions (route B). 
 
The alternative route to synthesize the diallylpurines involves N-allylation before C-8 
functionalization as the key steps (Scheme 54). 
C-8 functionalization was attempted by various methods including lithiation / halogenation, 
organomagnesium, and organoindium addtions. 
 
 
Scheme 54. Steps (a) N-allylation, (b) C-6 amination, (c) lithiation/halogenation, Grignard 
addition, or organoindium addition. 
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3.2.1 Synthesis of 9-allyl-6-chloro-9H-purine (19) and 7-allyl-6-chloro-7H-purine (20). 
 
6-Chloropurine 16 was N-allylated with allyl bromide in the presence of potassium carbonate. 
The reaction had run for 20 h in DMF at room temperature (Scheme 55).
22 
 
 
 
Scheme 55. 
 
Both the N-9 and N-7 allylated isomers were formed with the latter as the minor isomer.  The 
1
H NMR spectrum of the crude product showed the isomer distribution of (N9/N7) to be 2.4 : 
1, and the products 19 and 20 were isolated in 62% (Lit.
22
 59 %) and 21% (Lit.
22
 20%) yields, 
respectively, by flash chromatography. 
 
3.2.2  Synthesis of 9-allyl-6-(piperidin-1-yl)-9H-purine (33). 
 
Usually, most purine substrates are insoluble in water, thus the vast majority of purines 
reactions are done in organic media. Interestingly, amination of N-allylated 6-chloropurines 
by piperidine are done successfully in water as a non-toxic environmentally friendly solvent.  
 
According to the literature, the synthesis of compound 33 was done in water by microwave 
irradation
34
 (84% yield) as well as by heating-induced method
32
 (95% yield). 
We had achieved amination of 9-allyl-6-chloropurine 19 with piperidine as a heterocyclic 
amine.  Reflux for 24 hours in H2O at 100 °C gave 95% yield cleanly without further 
purifications (Scheme 56).
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Scheme 56. 
There was a mismatch of the measured melting point of compound 33 (80-82 oC) to what is 
reported in literature (54-56 oC).
34 
This gap can only be attributed to a misprint or 
mismeasurement in literature since all other data and structure elucidation refer to the 
indicated compound. 
 
3.2.3  Synthesis of 7-allyl-6-(piperidin-1-yl)-7H-purine (95). 
 
Applying the previous procedure (Chapter 3.2.2), amination of 7-allyl-6-chloropurine 20 by 
piperdine in H2O for 24 h was achieved to obtain a pure product in a high yield (92%) without 
chromatographic purification (Scheme 57). 
 
 
Scheme 57. 
 
HMBC NMR was employed to confirm the structure of compound 95. Long-range coupling 
was observed between the two symmetrical NCH2 in piperidinyl ring and C-6, besides 
coupling of N(7)CH2 with both C-5 and C-8 to indicate that compound 95 is the correct one 
(Table 8). 
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Table 8. Selected correlation from long range HMBC NMR spectrum for compound 95. 
X = coupling between carbon and proton 
 
 
 
3.2.4  C-8 functionalization via lithiation 
 
3.2.4.1  Synthesis of 9-allyl-8-chloro-6-(piperidin-1-yl)-9H-purine (96) and (Z)-8-chloro-
6- (piperidin-1-yl)-9-(prop-1-en-1-yl)-9H-purine (97). 
 
Lithiation of 9-allyl-6-(piperidin-1-yl)-9H-purine 33 by LDA prepared in situ followed by 
chlorination with hexachloroethane was achieved. The reaction afforded the 8-chloropurine 
96 in a low yield (31%) and the 9-alkenylpurine 97 (22% yield), beside several other 
compounds which probably resulted from deprotonation / lithiation / chlorination of the 
allylic side chain, but they could not be isolated in pure form (Scheme 58). 
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Scheme 58.  
 
According to HMBC NMR of compound 96, long-range correlations of NCH2 in the allyl 
group with =CH2, =CH, C-8, and C-4 had proved the correct structure (Table 9).  
 
Table 9. Selected correlation from long range HMBC NMR spectrum for compound 96. 
X = strong coupling between carbon and proton. 
x = weak coupling between carbon and proton. 
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According to 
1
H NMR spectrum for compound 97, the coupling constant between the two 
protons around the double bond of the N-9 propenyl group equals 8.0 which is typical for Z-
alkenes.
115
 
On the other hand, HMBC NMR of product 97, showed couplings of CH3 with NCH=, CH=, 
and C-8 (Table 10).  
 
Table 10. Selected correlation from long range HMBC NMR spectrum for compound 97. 
X = strong coupling between carbon and proton. 
x = weak coupling between carbon and proton. 
 
 
3.2.4.2 Synthesis of 6,8-dichloro-9-ethyl-9H-purine (49). 
In order to make sure that the problems encountered in the previous reaction (Chapter 3.2.4.1) 
is attributed to the allyl group not to the LDA generation in the first step, lithiation of 6-
chloro-9-ethyl-9H-purine 27a was done, following a literature procedure,
21
 using lithium 
diisopropylamide (LDA) which was prepared in situ by reacting a titrated n-BuLi with 
diisopropylamine in dry conditions at -78 °C under inert atmosphere using dry THF as a 
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solvent. Lithiation was followed by chlorination with hexachloroethane as a good 
electrophilic donor to afford compound 49 in 71% yield (Lit.
21
 74%) (Scheme 59). 
 
Scheme 59. 
3.2.4.3 Synthesis of (Z)-6-(piperidin-1-yl)-9-(prop-1-en-1-yl)-9H-purine (98) 
In order to explore the influence of LDA on N-9 allylated purine, compound 33 was subjected 
to freshly prepared LDA then quenched with NH4Cl (aq). The obtained products were 37% of 
unaffected starting material 33 and 23% of N-propenylpurine 98 (Scheme 60). 
It is well-observed through literature reactions on N-allylpurines that strong bases could 
induce the rearrangement of the N-allylic side chains.
21,100, 112,114
 Thus, LDA could readily 
deprotonate the allyl chain and induce the double bond migration.  
 
Scheme 60. 
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Rearrangement occurred in favor of the formation of compound 98 in complete selectivity 
towards cis-configuration. However the low yield of compound 98 may be attributed to the 
competition between lithiation at C-8 and the allyl group, subsequent allylic anions formed 
might revert again to the allylpurine 33 upon protonation. 
According to the 
1
H NMR spectrum of compound 98, the vicinal coupling constant (
3
J) 
between the two protons of NCH=CH equals 8.6 which is correspondent to cis- alkenes.
115 
Structure elucidation of compound 98 by HMBC NMR spectrum had shown diagnostic long-
range coupling of the terminal CH3 in the propenyl group with all of NCH=, CH=, C-8, and 
C-4 which confirm the structure of the product obtained (Table 11). 
 
Table 11. Selected correlation from long range HMBC NMR spectrum for compound 98. 
X = strong coupling between carbon and proton. 
x = weak coupling between carbon and proton. 
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3.2.4.4  Attempt to trap the C-lithiated purine with allyl bromide. 
Lithation of 9-allyl-6-(piperidin-1-yl)-9H-purine 33 using LDA prepared in situ followed by 
allylation by allyl bromide did not succeed and 96% of the starting material was recovered 
again with nothing else formed according to TLC and the 
1
H NMR spectrum (Scheme 61). 
 
 
Scheme 61. 
 
No double bond migration happened to the allyl group as it was confirmed in the previous 
reactions (Chapters 3.2.4.1 and 3.2.4.3) and the starting material was recovered again in 
almost the same amount. Therefore, the failure of this reaction could be attributed to 
insufficient dry conditions used; hence the LDA was not generated in the first step.  
However, this reaction was replaced with another convenient and more effective route to 
synthesize compound 71 without involving the double bond migration of the allylic side chain 
which is resulted from LDA impact, and the subsequent significant decrease in the obtained 
yield of the desired product. 
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3.2.5  C-8 allylation  of 9-allylpurine by organomagnesium or organoindium addition 
reaction. 
Since C-8 lithiation / halogenation / allylation route towards compound 71 was inconvenient 
due to influence of LDA on the N-9 allyl group and the low yield obtained for the desired 
product, direct allylation via organometallic reagent would be a real improvement.  
To the best of our knowledge, direct C-8 allylation using an organometallic reagent was 
reported twice before in the literature, first, on 6-chloro-9-tetrahydropyranylpurine via Gilman 
reagent generated from allylmagnesium bromide and CuI,
116 
second, on 9-benzyl-2-chloro-6-
iodopurine by allylmagnesium bromide to give the corresponding 8-allyl-7,8-dihydropurine in 
37% yield.
55 
Based on Grignard addition to carbonyl compounds,
18
 a mechanism of the addition reaction 
via allylmagnesium bromide on C=N in purine is proposed (Scheme 62). 
 
 
Scheme 62. Proposed general mechanism of Grignard addition on purines. 
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3.2.5.1 Synthesis of 8,9-diallyl-6-(piperidin-1-yl)-9H-purine (71) 
Improving literature procedure for C-8 allylation of purines via Grignard reagent,
55
 synthesis 
of compound 71 was carried out by allylmagnesium bromide on 9-allyl-6-(piperidin-1-yl)-9H-
purine 33 at 0 °C in THF as a solvent (Scheme 63). 
 
 
Scheme 63. 
 
The anticipated product was the adduct compound 99 (Figure 11) according to the mechanism 
of Grignard addition, but fortunately, the rearomatized compound was obtained without using 
an oxidizing agent probably due to a quick self-oxidation by atmospheric oxygen during the 
work-up  as well as the high tendency of this compound 99 towards the more stable aromatic 
form. 
 
Figure 11. 
Endeavoring for the optimization of this reaction, reaction times and amounts of 
allylmagnesium bromide were varied (Table 12). Running the reaction for 4 h with 3.00 
equivs. of Grignard reagent had the optimal conversion (95%) and yield (89%) without any 
noticeable effect on N-9 allyl group or any potential double migration. Moreover, running the 
reaction with the same amount (3.00 equivs) for longer time (6 h) did not lead to any higher 
conversion (Table 12). 
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Table 12. Synthesis optimization of compound 71 via Grignard addition.  
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3.2.5.2  Synthesis of 8,9-diallyl-6-chloro-9H-purine (100a) 
Compound 100a was synthesized via three methods depending mainly on employing 
organometallic coupling towards direct C-8 allylation (Scheme 64). 
Scheme 64. 
 
Method A. 
Method A for C-8 allylation was carried out on 9-allyl-6-chloro-9H-purine 19 via Grignard 
reagent, allylmagnesium bromide, at 0 °C in THF as a solvent (Scheme 65). 
 
 
Scheme 65. 
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6-Chloropurine 19 showed to be more reactive towards Grignard addition compared to the 6-
piperidinylpurine 33 (Chapter 3.2.5.1), the reaction was run only for 20 min which is much 
shorter time compared to reaction time for synthesis of compound 71 previously (4 h) 
(Scheme 63).  
Moreover, less amount of Grignard reagent was required (2.12 equivs) to get a high 
conversion (> 97%). In contrary to 6-piperidinylpurine 33, 6-chloropurine 19 proved to form 
the adduct compound 100b as the major product as well as the aromatized compound 100a as 
the minor product. The two products were isolated by flash chromatography and that gave rise 
to compound 100a (10% yield) and compound 100b (74% yield).  
According to HMBC NMR spectrum for compound 100a, the diagnostic long-range 
couplings between CH2 attached to C-8 with C-5 and C-6, and =CH in N-9 allyl with C-2 
have established that the 8,9-diallylpurine 100a is the correct compound (Table 13). 
Table 13. 
1
H-
13
C correlations from long range HMBC NMR spectrum for compound 100a. 
X = coupling between carbon and proton. 
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Mass spectrometry (ESI) of adduct 100b gave for the calculated value of C11H13N4Cl [M+H]
+
 
237.0829 and the found value was 237.0901 which proves the presence of two extra protons 
than the aromatized compound 100a. 
HMBC NMR spectrum for compound 100b had shown diagnostic long-range couplings of 
N(9)CH2 with C-4 exclusively which does not appear with C(8)CH2, strong coupling between 
C-8 with =CH2 in C-8 allyl while it is weak with CH2 in N-9 allyl, strong coupling of H-8 
with C(8)CH2, C-6, C-5, =CH in C-8 allyl, and C-4 besides a weak coupling with N(9)CH2 
(Table 14). 
Table 14. 
1
H-
13
C correlations from long range HMBC NMR spectrum for compound 100b. 
X = strong coupling between carbon and proton. 
x = weak coupling between carbon and proton. 
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Method B. 
According to method A discussed, two compounds were obtained, the major was the adduct 
compound containing non-aromatized imidazole ring 100b and the minor was the oxidized 
product with aromatized imidazole ring 100a. The latter one is the desired compound for 
proceeding with cyclization. Thus, the crude product of the reaction was oxidized using 
activated manganese dioxide in DCM at room temperature to recover the aromaticity of 
imidazole ring in the purine skeleton of compound 100b. The product was purified by flash 
chromatography to give 73% yield of compound 100a (Scheme 66). 
 
Scheme 66. 
 
Method C. 
Indium reacts more readily with electron-deficient heterocycles
62-66 
than other metals, such as 
Mg, Pb, Bi, or Zn and does not require a promoter or flammable organic solvent to drive the 
reaction. Indium-mediated allylation have advantages over other carbon-carbon bond forming 
reactions because of their ability to be carried out in water, which is cheap and 
environmentally friendly. Therefore, these reactions represent green chemistry. Reactions 
yield a few by-products making it easy to purify the desired product.  
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In contrary of Gringard reagents, indium-mediated allylation provides a safer alternative since 
the reactive indium intermediate can be generated in situ from a mixture of indium metal, the 
desired allylic halide, and the electrophile. Therefore, no synthesis or handling of unstable 
Grignard reagents is required. 
To the best of our knowledge, indium-mediated allylation has not been achieved on purine 
substrates before. Thus, it would be a novel route to attempt. 
Based on organoindium addition to carbonyl compounds,
18
 a mechanism of the addition 
reaction by monoallylindium dibromide on C=N in purine is proposed (Scheme 67). 
 
 
Scheme 67. 
 
An attempt was done trying to react 9-allyl-6-chloropurin 19 with indium powder (8 equivs.) 
and allyl bromide (12 equivs.) in refluxing THF, but that gave an unidentified product 
probably because of the unsuitable reaction temperature for the organometallic addition 
reaction (Scheme 68 and Table 15). 
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Table 15. Attempts towards compound 100a. 
 
However, the reaction was accomplished successfully when it was run at room temperature 
for 24 h using the same amount of indium metal (8 equivs.) and allyl bromide (12 equivs.) to 
lead to 89% conversion affording mainly the adduct compound 100b as the major product, 
according to the 
1
H NMR of the crude product, which required oxidation to retrieve the 
aromaticity.  
The oxidation was achieved by MnO2 in DCM for 2 h at room temperature then the product 
was purified by flash chromatography to obtain 48% yield of the isolated product 100a 
(Scheme 68).  
 
 
Scheme 68. 
 
The reason behind the moderate yield obtained in spite of the good conversion is due to 
difficulties encountered in the work-up after the first step. A thick white emulsion was formed 
after quenching the reaction with NH4Cl (aq.) which caused difficulties in the extraction and 
consequently loss in the product. 
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3.2.5.3 Attempts to synthesize 8,9-diallyl-6-(piperidin-1-yl)-9H-purine (71) by 
organoindium addition reaction. 
Other attempts were done on 6-piperdinyl-9-allylpurine 33 with variations in indium amount 
(2 -10 equivs.), allyl bromide amount (3 - 15 equivs.), and reaction temperature (rt - reflux) 
but unfortunately that did not succeed (Scheme 69 and Table 16). 
 
 
Scheme 69. 
Table 16. Attempts towards compound 71. 
 
 
It is well-realized from Grignard addition previously and organoindium addition, that 6-
chloro-9-allylpurine 19 is more reactive towards organometallic reagents than 6-piperdinyl-9-
allylpurine 33. Hence, the latter one has a promising scope for further studies, and moreover, 
improvements of the work-up for indium-mediated allylation. 
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3.2.6. C-8 allylation of 7-allylpurines by organomagnesium addition reaction. 
3.2.6.1 Synthesis of 7,8-diallyl-6-(piperidin-1-yl)-7H-purine (103) 
C-8 allylation of 7-allyl-6-piperidinylpurine 95 was attempted using various amounts of 
allylmagnesium bromide (1.00 - 3.00 equivs.) and reaction times (20 min - 6 h) at the same 
temperature (0 °C), but that mostly led to a mixture of the adduct compound 101 and another 
compound whose introduced C-8 allyl group has a migrated double bond 102 (Figure 12).  
 
 
Figure 12. 
 
Realizing that the adduct compound was formed by the Grignard addition, thus MnO2 was 
added to the crude product from the first step to recover the aromaticity and isolate the desired 
product. 
In some attempts, both compounds 103 and 104 were obtained as a mixture and could not be 
separated by flash chromatography (Table 17). 
According to 
1
H NMR, Compound 104 proved to have a trans C-8 propenyl group whose two 
protons around the double bond had a vicinal coupling constant (
3
J) = 15.3 which is typical 
for E-alkenes.
115 
 
Although the corresponding N-9 allylated compound has previously required 3.00 equivs. of 
Grignard reagent for 4 h, but in this case (Scheme 70 and Table 17), the reaction was 
successfully controlled by using 2.00 equivs. of allylmagnesium bromide for only 40 min at 0 
°C to afford 85% yield which indicates the reactivity of 7-allylpurines compared to 9-allyl 
purines. 
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Scheme 70. 
Table 17. Attempts to synthesize the 7,8-diallylpurine 103. 
 
In order to elucidate the structure of compound 103, the HMBC NMR spectrum was 
employed to indicate diagnostic long-range couplings of =CH2 in C-8 allyl group with C-8 
while =CH2 in N-7 allyl did not show this coupling with C-8, besides coupling between =CH 
in C-8 ally with C-8 while =CH in N-7 allyl did not show such coupling with C-8 which 
established that 7,8-diallyl 103 was obtained (Table 18). 
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Table 18. 
1
H-
13
C correlations from long range HMBC NMR spectrum for compound 103. 
X = strong coupling between carbon and proton. 
x = weak coupling between carbon and proton. 
 
 
3.2.6.2. Synthesis of 7,8-diallyl-6-chloro-7H-purine (105a), (E)-7-allyl-6-chloro-8-(prop-
1-en-1-yl)-7H-purine (105b), and (E)-3-(7-allyl-6-chloro-7H-purin-8-yl)acrylaldehyde 
(105c). 
Several attempts were done for C-8 allylation of 7-allyl-6-chloropurine 20 using 
allylmagnesium bromide at 0 °C but it was obvious that the target compound 105a was not 
stable enough towards Grignard reagent which affected the introduced allyl group and caused 
the double bond migration.  
In order to control this kind of rearrangement, the reaction temperature was decreased to -20 
°C using (1:3 NaCl / ice) bath and the reaction was run for only 5 min. Definitely, the rate of 
the double bond migration was decreased significantly but not completely. After the oxidation 
of the crude product with MnO2 to rearomatize the adduct formed by Grignard addition, a 
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mixture of three compounds were obtained in a ratio (105a/105b/105c) (72%:20%:8%) but 
could not be isolated in a pure form due the intimate proximity of their TLC Rf  values in 
different eluent systems (Scheme 71). 
 
Scheme 71. 
The possible reasons for aldehyde formation could be the oxidation of the terminal methyl 
group of C-8 propenyl in compound 105b with MnO2 to the aldehyde group, or the oxidation 
of the methyl group during the flash chromatography on the silica gel in the presence of the 
MnO2.  
It was reported in literature
104
 that 3-formyl-2-methyl-substituted and 2-formyl-3-methyl-
substituted indoles are oxidized to the dialdehyde upon treatment with MnO2
 
which could 
explain the oxidative effect of MnO2 on the terminal methyl group of compound 105b in our 
case.  
The desired diallylpurine 105a could not be isolated in a pure form by flash chromatography, 
so we did not proceed with RCM reaction for this compound. 
HMBC NMR spectrum for the diallylpurine 105a refers to a long-range coupling of both 
NCH2 and C(8)CH2 with C-8 while exclusive coupling of  NCH2 with C-6 (Table 19). 
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Table 19.  
1
H-
13
C correlations from long range HMBC NMR spectrum for compound 105a.  
X = coupling between carbon and proton. 
 
 
According to 
1
H NMR, compound 105b had a trans- propenyl group where its 
3
J value = 15.2 
while HMBC NMR indicated that the migration of the double bond had occurred in C-8 allyl 
group not N-7 allyl group where NCH2 showed coupling with both of =CH2 and CH= in N-7 
allyl group, besides C-6 exclusively, on the other hand, CH= in C-8 allyl group coupled with 
the terminal CH3 and C-8 (Table 20). 
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Table 20.  
1
H-
13
C correlations from long range HMBC NMR spectrum for compound 105b.  
X = coupling between carbon and proton. 
 
 
Mass spectrometry (ESI) of the aldehyde 105c gave for the calculated value of C11H11N4Cl 
[M+H]
+
 249.0465 and the found value was 249.0672 which indicates the formation of the 
aldehyde 105c. 
Furthermore, the propenyl aldehydic side chain of compound 105c was the trans- isomer 
since its 
3
J = 15.5, according to 
1
H NMR spectrum. 
HMBC NMR confirmed the structure of compound 105c where NCH2 coupled with both 
CH= and =CH2 in N-7 allyl group, while C(8)CH= had correlations with both C(8)CH=CH 
and CHO, on the other hand CHO coupled with C(8)CH=CH (Table 21). 
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Table 21.  
1
H-
13
C correlations from long range HMBC NMR spectrum for compound 105c.  
X = coupling between carbon and proton. 
 
 
3.2.6.3 Synthesis of 8-allyl-6-chloro-7-methyl-7H-purine (106a), (E)-6-chloro-7-methyl-8-
(prop-1-en-1-yl)-7H-purine (106b), and (E)-3-(6-chloro-7-methyl-7H-purin-8-
yl)acrylaldehyde (106c). 
Besides the NMR structures elucidations that were done for the compounds of the previous 
reaction (Scheme 71), we wanted to make sure which allyl group (N-7 allyl or the introduced 
N-8 allyl) had undergone a double bond migration, and on the other hand, to reveal if the N-7 
allyl was playing a role in driving the double bond migration (Scheme 71).  
Thus, the same procedure in the previous reaction (Scheme 71) was used for C-8 allylation of 
compound 18 by allylmagnesium bromide at -20 °C for 20 min. There was still a ratio of the 
double bond rearrangement. The crude product was treated with MnO2 to oxidize the formed 
adduct affording a mixture of three compounds (106a/106b/106c) (72:20:8) (Scheme 72). 
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Scheme 72. 
This reaction indicates that, in the previous case (Scheme 71), the double bond migration 
happened in the newly introduced C-8 allyl group, on the other hand, the N-7 allyl was not 
related directly to the double migration but definitely it has increased the instability of the 
molecule, thus reaction time was decreased to 5 min in the previous case compared to 20 min 
in this case. 
Structure confirmation for the major compound 106a by the HMBC NMR indicates to long 
range coupling of =CH2 in C-8 allyl with C(8)CH2 and =CH in the allyl group, while NCH3 
correlates exclusively with C-6 (Table 22). 
Table 22.  
1
H-
13
C correlations from long range HMBC NMR spectrum for compound 106a. 
X = strong coupling between carbon and proton. 
x = weak coupling between carbon and proton. 
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Compound 106b was formed as the trans- isomer exclusively where the vicinal coupling 
constant (
3
J) between the two protons of C(8)CH=CH equaled 15.5, according to 
1
H NMR 
spectrum. 
Long-range HMBC NMR spectrum of compound 106b refers to correlations of NCH3 with C-
5, C(8)CH=CH with C-8, besides coupling of the terminal CH3 in the propenyl group with  
both C(8)CH=CH and C(8)CH (Table 23). 
Table 23.  
1
H-
13
C correlations from long range HMBC NMR spectrum for compound 106b. 
X = coupling between carbon and proton. 
 
Moreover, the aldehyde 106c was formed probably because the oxidation of the terminal 
methyl group for compound 106b by MnO2 to the aldehyde group. 
Mass spectrometry (ESI) of the aldehyde 106c gave for the calculated value of C9H7N4OCl 
[M+H]
+
 223.0308 and the found value was 223.0412 which indicates the formation of the 
aldehyde 106c. 
Compound 106c formed had trans- configuration, according to the  
1
H NMR, with 15.5 
3
J 
value between the both protons of   C(8)CH=CH. 
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According to HMBC NMR spectrum of compound 106c, the proton of the aldehyde group 
couples with C(8)CH=CH and on the other hand, C(8)CH couples with CHO which indicates 
to the correct compound (Table 24). 
Table 24.  
1
H-
13
C correlations from long range HMBC NMR spectrum for compound 106c. 
X = coupling between carbon and proton. 
 
 
3.3  Ring closing metathesis and aromatization of the ring formed. 
 
Attempts to cyclize the diallylpurine derivatives 71 and 100a were done using Grubbs’ 2nd 
generation catalyst followed by rearomatization of the cyclized compounds by DDQ as an 
oxidizing agent to obtain the pyrido[1,2-e]purine derivatives. 
3.3.1  Ring closing metathesis reactions 
3.3.1.1 Synthesis of 4-(piperidin-1-yl)-6,9-dihydropyrido[1,2-e]purine (74). 
Following a literature procedure,
23 
ring closing metathesis was applied on 8,9-diallyl-6-
(piperidin-1-yl)-9H-purine 71 using 19% Grubbs 2
nd
 generation catalyst 69 (Figure 13) (four 
portions each after 2 h) in DCM for 48 h at room temperature (Scheme 73). Product 74 was 
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purified by flash chromatography to give 94% yield, slightly less than what is reported in 
literature (97%).
23 
 
 
 
Figure 13. Grubbs' 2
nd
 generation catalyst. 
 
 
 
 
Scheme 73. 
 
Attempts were done to reduce the catalyst loading and run the reaction in refluxing DCE 
instead of DCM at room temperature to enhance the reaction by heating. 5% of catalyst for 48 
h. led to a moderate yield, while 10% catalyst gave a fairly good yield. A comparison between 
the three methods that were used is summarized in Table 25.  
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Table 25. RCM of 8,9-diallyl-6-(piperidin-1-yl)-9H-purine 71. 
 
 
3.3.1.2  Synthesis of 4-chloro-6,9-dihydropyrido[1,2-e]purine (107). 
When the literature procedure for RCM
23
 was applied on the 6-chloropurine 100a by Grubbs’ 
2
nd
 generation catalyst 69 (added in four portions each after 2 h) in DCM for 48 h at room 
temperature, the conversion was incomplete (77%) and the obtained yield for the isolated 
cyclized compound 107 was 74%.  
It was obvious that these conditions are not optimal for this substrate and 6-chloropurine 100a 
is less reactive towards RCM at room temperature than piperidine derivative 71. Thus, the 
reaction conditions were changed to refluxing DCE which has a higher boiling point than 
DCM. That led to a complete conversion only after 6 h affording an excellent yield (98%). 
Furthermore, the catalyst loading was decreased in several attempts; a complete conversion 
was obtained for at least 8% catalyst added in one portion (Scheme 74 and Table 26).  
 
 
Scheme 74. 
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Table 26. RCM optimization of compound 100a. 
 
Table 27. 
1
H-
13
C correlations from long range HMBC NMR spectrum for compound 107. 
X = coupling between carbon and proton. 
x = weak coupling between carbon and proton. 
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According to the HMBC NMR spectrum for compound 107, diagnostic long-range couplings 
were observed for C(8)CH2 with C-5 and weak coupling with C-6, besides coupling of 
N(9)CH2 with C-4 which indicates to the correct compound 107 (Table 27). 
 
3.3.1.3  Attepmpts to cyclize 7,8-diallyl-6-(piperidin-1-yl)-7H-purine (103) 
Attempts to cyclize the 7,8-diallyl compound 103 following the previous successful 
procedures for the corresponding 8,9-diallyl via Grubbs’ 2nd generation catalyst failed 
(Scheme 75). 
 
 
Scheme 75. Reagents and conditions: (a) Grubbs’ II cat. (19%), DCM, rt, 48 h; (b) Grubbs’ II 
cat. (14%), DCE, , 48 h. 
The reaction was tried in both DCM at room temperature and in refluxing DCE for 48h. In 
both cases the reaction did not proceed as it was expected. The crude product was attempted 
to be purified by flash chromatography. According to 
1
H NMR of the resulted product, the 
starting material had been consumed but with no indication to the desired product 108.  
It is not understood exactly what happened for the starting material 103 but it was reported in 
literature
114
 that a ruthenium catalyst (not RCM catalyst used in our case) could drive the 
double bond migration for both N-9 allyl and N-7 allyl of purines (Scheme 76). Thus, might 
be the starting material 103 had decomposed under the effect of the ruthenium catalyst which 
induced the double bond migration. 
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Scheme 76. Reagents and conditions: (a) Cat. RuClH(CO)(PPh3)3, xylenes, Δ.
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Moreover, we could realize from the Grignard additions done on 7-allylated purines that the 
formed 7,8-diallyl products are unstable in the presence of base and undergo double bond 
migration easily. 
 
3.3.2    Oxidation of RCM products 
3.3.2.1 Synthesis of 4-(piperidin-1-yl)pyrido[1,2-e]purine (7). 
Compound 74 was oxidized by DDQ (2 equivs.) in DCM at room temperature to get a 
complete conversion, according to the crude product 
1
H NMR and TLC, after 24 h. The 
product was purified by flash chromatography to afford the cytotoxic pyrido[1,2-e]purine 7
1
 
in 87% yield (Scheme 77). 
 
 
Scheme 77. 
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3.2.2.2  Synthesis of 4-chloropyrido[1,2-e]purine (9). 
In contrast to piperidine 74, DDQ-mediated oxidation of chloride-containing compound 107 
in DCM at room temperature for 24 h did not lead to any conversion at all. Carrying out the 
reaction in refluxing DCE led to a complete conversion, according to the crude product 
1
H 
NMR and TLC, after only 6 h. The product was purified by flash chromatography to afford 
91% yield (Scheme 78). 
 
 
Scheme 78. 
Oxidation of chloride-containing compound 107 proved that this substrate is less reactive in 
room temperature but remarkably affected by heating to give the desired product in shorter 
time compared to piperidine compound 74.  
The significance of this adopted synthetic route towards compound 9 starting with N-9 
allylation, C-8 allylation, RCM, and finally the oxidation are, first, the high yields afforded, 
second, the pyrido[1,2-e]purines which has been studied as DNA intercalating agents vary 
mostly by their 4-substituent. Thus, the 4-substituent can be introduced in the last step. 
Compound 9 was converted previously into DNA intercalators such as piperidine 7
1
 and other 
amines (Scheme 79). 
 
 
Scheme 79. Reagents and conditions: (References 1, 2, and 117). 
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4. CONCLUSION 
 
In the synthesis towards 4-substituted pyrido[1,2-e]purines, the original route involving  C-8 
bromination of purine followed by N-allylation have shown to be inefficient route due to the 
low yield obtained for the desired N-9 allylated isomer. 
On the other hand, the alternative route involving N-allylation of purine followed by C-8 
functionalization has proved to be efficient way with some modifications. The major product 
of N-allylation was the desired N-9 allyl isomer.  
In order to introduce the allyl group onto C-8 position, lithiation followed by chlorination was 
done. Unfortunately, LDA influenced the N-9 allyl group resulting in rearrangement of the 
double bond and consequently low yielding of the desired compound. 
Attempting to employ organometallic reagent, to directly allylate C-8 position was a real 
improvement. It has proved to be an efficient and high yielding method to synthesize 8,9-
diallylpurines which are key compounds for further syntheses of cytotoxic pyrido[1,2-
e]purines. 
Organometallic additions to synthesize 7,8-diallylpurines have shown to be inconvenient due 
to the double bond migration happened in the introduced allyl group in position-8. 
Ring closing metathesis of 6-piperidinyl-8,9-diallylpurine was done at room temperature 
followed  by oxidation with DDQ. 
On the other hand, ring closing metathesis of 6-chloro-8,9-diallylpurine has proved to be more 
efficient at DCE refluxing temperature more than the room temperature. The RCM product 
was rearomatized by DDQ in a convenient way. 
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5. EXPERIMENTAL 
 
The 
1
H NMR spectra were acquired on a 400 MHz on a Bruker AVII 400 instrument or at 200 
MHz on a Bruker Avance DPX 200 instrument and the 
1
H decoupled. 
13
C NMR spectra were 
recorded at 100 MHz using the Bruker AVII 400 spectrometer. Assignments of 
1
H and 
13
C 
resonances were based on HMBC and HSQC NMR. Mass spectra under electron impact 
conditions were recorded with a VG Prospec instrument at 70 eV ionizing voltage, and are 
presented as m/z (% rel. int.). Electrospray MS spectra were recorded with a Bruker Apex 47e 
FT-ICR mass spectrometer. Dry THF and DCM were obtained from a solvent purification 
system, MB SPS-800 from MBraun, Garching, Germany. Melting points were determined on 
a Büchi Melting Point B-545 apparatus and are uncorrected. 
Diisopropyl amine was distilled from calcium hydride and stored under N2 over dry molecular 
sieves. n-BuLi was titrated against diphenylacetic acid and dry THF was used as a solvent.
118
 
Allylmagnesium bromide was titrated against menthol as anhydrous protic reagent in the 
presence of 1,10-phenanthroline as a colour-indicator and dry THF was used as a solvent.
119
 
All other reagents were commercially available and used as received.  
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9-Allyl-6-chloro-9H-purine (19) and 7-allyl-6-chloro-7H-purine (20) 
 
 
 
Potassium carbonate (4.15 g, 30.0 mmol) was added to a stirred solution of 6-chloropurine 16 
(1.58 g, 10.2 mmol) in dry DMF (40 mL) at ambient temperature under N2. After 20 min., 
allyl bromide (1.70 mL, 19.7 mmol) was added and the resulting mixture was stirred for 20 h, 
filtered and evaporated in vacuo. The crude product was purified by flash chromatography on 
silica gel eluting first with 0.5 % MeOH in DCM followed by 1 % MeOH in DCM. This gave 
1.24 g (62%) of 9-allyl-6-chloro-9H-purine 19 as a colourless solid and 430 mg (21%) of 7-
allyl-6-chloro-9H-purine 20 as a yellow solid. 
 
9-Allyl-6-chloro-9H-purine (19) 
1
H NMR (CDCl3, 400 MHz) δ 4.89 (dt, J = 5.7, 1.6 Hz, 2H, CH2), 5.25 (dt, J = 17.0, 1.6 Hz, 
1H, =CH2a), 5.35 (dt, J = 10.2, 1.6 Hz, 1H, =CH2b), 5.98-6.09 (m, 1H, =CH), 8.12 (s, 1H, H-
8), 8.74 (s, 1H, H-2). 
13
C NMR (CDCl3, 400 MHz) δ 46.3 (CH2), 120.0 (=CH2), 130.9 (=CH), 131.6 (C-5), 144.9 
(C-8), 151.1 (C-4), 151.7 (C-6), 152.1 (C-2).  
MS (EI).  m/z (rel. %): 196/194 (28/87, M
+
), 193 (100), 169 (8), 167 (27), 154 (12), 132 (10), 
119 (6), 77 (6). 
HR-MS. Found 194.0355 calculated for C8H7N4Cl 194.0359. 
M.p. 76-78 oC (Lit.
22
 79.6-80.1 
o
C) 
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Spectrum 1. 
1
H NMR of 9-allyl-6-chloro-9H-purine (19). 
 
Spectrum 2. 
13
C NMR of 9-allyl-6-chloro-9H-purine (19). 
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7-Allyl-6-chloro-9H-purine (20) 
1H NMR (CDCl3, 400 MHz) δ 5.08-5.17 (m, 3H, CH2 and =CH2a), 5.37 (d, J=10.2 Hz, 1H, 
=CH2b), 6.01-6.15 (m, 1H, =CH), 8.22 (s, 1H, H-8), 8.87 (s, 1H, H-2). 
13
C NMR (CDCl3, 100 MHz) δ 49.2 (CH2), 119.5 (=CH2), 122.4 (C-5), 131.7 (=CH), 143.0 
(C-6), 148.8 (C-8), 152.5 (C-2), 161.9 (C-4).  
MS (EI).  m/z (rel. %): 196/194 (35/100, M
+
), 167 (10), 159 (8), 132 (19), 105 (6), 77 (5). 
HR-MS: Found 194.0364 calculated for C8H7N4Cl 194.0359. 
M.p. 89-91 oC (Lit.
22
 92.8-93 
o
C) 
 
 
 
 
 
 
Spectrum 3. 
1
H NMR of 7-allyl-6-chloro-9H-purine (20). 
93 
 
 
Spectrum 4. 
13
C NMR of 7-allyl-6-chloro-9H-purine (20). 
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9-Allyl-6-(piperidin-1-yl)-9H-purine (33) 
 
A mixture of compound 19 (864 mg, 4.44 mmol) and piperidine (0.88 mL, 8.913 mmol) in 
H2O (8 mL) was refluxed for 24 h. After cooling, the mixture was extracted with DCM (2 x 
20 mL) and the organic layer was washed with H2O (2 x 20 mL), dried with MgSO4 and 
evaporated in vacuo. to give 1.023 g (95%) 9-allyl-6-(piperidin-1-yl)-9H-purine 33 as a 
colourless solid. 
 
1
H NMR (CDCl3, 400 MHz) δ 1.60-1.77 (m, 6H, 3 x CH2 in piperidinyl), 4.21 (brs, 4H, 2 x 
CH2 in piperidinyl), 4.76 (d, J = 5.6, 2H, CH2 in allyl), 5.14 (d, J = 17.1 Hz, 1H, =CH2a), 5.25 
(d, J = 10.2 Hz, 1H, =CH2b), 5.98-6.07 (m, 1H, =CH), 7.71 (s, 1H, H-2), 8.34 (s, 1H, H-8).  
13
C NMR (CDCl3, 100 MHz) δ 24.8 (CH2 in piperidinyl), 26.0 (2 x CH2 in piperidinyl), 45.5 
(CH2 in allyl), 46.3 (2 x CH2 in piperidinyl), 118.5 (=CH2), 119.7 (=CH), 132.1 (C-8), 137.7 
(C-4), 150.8 (C-2), 152.6 (C-6), 153.9 (C-5).  
MS (EI).  m/z (rel. %): 244/243 (20/100, M
+
), 228 (11), 214 (51), 202 (27), 187 (24), 174 
(22), 160 (19), 147 (8), 132 (6), 119 (10), 84 (11). 
M.p. 80-82 
o
C (Lit.
34
 54-56 
o
C). 
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Spectrum 5. 
1
H NMR of 9-allyl-6-(piperidin-1-yl)-9H-purine (33). 
Spectrum 6. 
13
C NMR of 9-allyl-6-(piperidin-1-yl)-9H-purine (33). 
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Spectrum 7. 
13
C DEPT NMR of 9-allyl-6-(piperidin-1-yl)-9H-purine (33). 
Spectrum 8. COSY NMR of 9-allyl-6-(piperidin-1-yl)-9H-purine (33). 
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Spectrum 9. HSQC NMR of 9-allyl-6-(piperidin-1-yl)-9H-purine (33). 
Spectrum 10. HMBC NMR of 9-allyl-6-(piperidin-1-yl)-9H-purine (33). 
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7-Allyl-6-(piperidin-1-yl)-7H-purine (95) 
 
A mixture of compound 20 (410 mg, 2.10 mmol) and piperidine (0.42 mL, 4.20 mmol) in 
H2O (5 mL) was refluxed for 24 h. After cooling, the mixture was extracted with DCM (2 x 
15 mL) and the organic layer was washed with H2O (2 x 15 mL), dried with MgSO4 and 
evaporated in vacuo. to give 471 mg (92%) 7-allyl-6-(piperidin-1-yl)-9H-purine 95 as a 
colourless solid. 
 
 
1
H NMR (CDCl3, 400 MHz) δ 1.64-1.79 (m, 6H, 3 x CH2 in piperidinyl), 3.28-3.37 (m, 4H, 2 
x CH2 in piperidinyl), 4.92 (d, J = 5.3 Hz, 2H, CH2 in allyl), 5.23 (d, J = 17.2 Hz, 1H, =CH2a), 
5.35 (d, J = 10.3 Hz, 1H,=CH2b), 5.98-6.05 (m, 1H, =CH), 8.04 (s, 1H, H-8), 8.67 (s, 1H, H-
2).  
 
13
C NMR (CDCl3, 100 MHz) δ 24.2 (CH2 in piperidinyl), 25.5 (2 x CH2 in piperidinyl), 48.5 
(CH2 in allyl), 51.2 (2 x NCH2 in piperidinyl), 115.8 (C-5), 119.2 (=CH2), 132.2 (=CH), 146.3 
(C-8), 152.4 (C-2), 156.2 (C-6), 161.3 (C-4). 
 
MS (EI). m/z (rel. %): 244/243 (22/93, M
+
), 228 (41), 214 (49), 159 (66), 84 (100).  
 
HRMS. Found 243.1477 calculated for C13H17N5 243.1484. 
 
M.p. 74-76 
o
C. 
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Spectrum 11. 
1
H NMR of 7-allyl-6-(piperidin-1-yl)-7H-purine (95). 
 
Spectrum 12. 
13
C NMR of 7-allyl-6-(piperidin-1-yl)-7H-purine (95). 
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Spectrum 13. COSY NMR of 7-allyl-6-(piperidin-1-yl)-7H-purine (95). 
 
 
Spectrum 14. HSQC NMR of 7-allyl-6-(piperidin-1-yl)-7H-purine (95). 
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Spectrum 15. HMBC NMR of 7-allyl-6-(piperidin-1-yl)-7H-purine (95). 
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6-(Piperidin-1-yl)-9H-purine (35)
33 
 
A solution of 6-chloropurine 16 (3.00 g, 19.40 mmol), piperidine (3.26 g, 38.4 mmol), and 
Et3N (13.42 mL, 96.23 mmol) in n-BuOH (195 mL) was stirred at 100 oC for 15 h. The 
mixture was cooled and concentrated on rotavapor to evaporate half of the amount of the 
solvent, and the white precipitate was triturated with MeOH (15 mL) three times. The white 
solid was collected and dried in vacuo. to give 3.44 g (87%) of 6-(piperidin-1-yl)-9H-purine 
35 as a colourless solid. 
 
1
H NMR (CDCl3, 400 MHz) δ 1.67-1.80 (m, 6H, 3 x CH2), 4.29 (brs, 4H, 2 x CH2), 7.95 (s, 
1H, H-8), 8.37 (s, 1H, H-2), 13.89 (brs, 1H, NH).  
13
C NMR (CDCl3, 100 MHz) δ 24.8 (CH2), 26.1 (2 x CH2), 46.4 (2 x NCH2), 119.5 (C-5), 
136.4 (C-8), 151.1 (C-4), 151.5 (C-2), 153.9 (C-6). 
MS (EI). m/z (rel. %): 204/203 (12/100, M
+
), 188 (15), 174 (78), 160 (31), 148 (33), 135 (22), 
120 (30), 93 (18), 84 (16). 
M.p. 275-277 
o
C. 
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Spectrum 16. 
1
H NMR of 6-(piperidin-1-yl)-9H-purine (35). 
Spectrum 17. 
13
C NMR of 6-(piperidin-1-yl)-9H-purine (35). 
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8-Bromo-6-(piperidin-1-yl)-9H-purine (24)
23
 
 
 
Compound 35 (116 mg, 0.57 mmol) and liquid bromine (0.22 mL, 4.28 mmol) were mixed 
and kept in a closed flask for 4 h, before the stopper was removed. The mixture was allowed 
to stand for 16 h., before the resulting solid was stirred in water (5 mL). Concentrated aqueous 
ammonia (10 mL) was added until dissolution and the solution neutralised with acetic acid. 
The precipitate was filtered, washed with water (5 mL), boiled in water (5 mL), and filtered 
while hot. Then, it was washed with water, acetone and ether, and dried in vacuo. to give 100 
mg (62%) of  8-bromo-6-(piperidin-1-yl)-9H-purine 24 as a yellow solid. 
 
1
H NMR (CDCl3, 400 MHz) δ 1.71-1.73 (m, 6H, 3 x CH2 ), 4.25 (brs, 4H, 2 x NCH2), 8.25 
(s, 1H, H-2),10.86 (brs, 2H, NH). 
13
C NMR (CDCl3, 100 MHz) δ 24.6 (CH2), 26.1 (2 x CH2), 46.6 (2 x NCH2), 121.3 (C-5), 
125.6 (C-8), 148.1 (C-2), 152.0 (C-4), 152.2 (C-6). 
MS (EI). m/z (rel. %): 283/281 (46/47, M
+
), 254 (30), 252 (30), 228 (11), 226 (11), 202 (100), 
174 (18), 147 (11).  
HRMS. Found 281.0278 Calculated for C10H12N5Br 281.0276. 
M.p. 212- 214 
o
C. 
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Spectrum 18. 
1
H NMR of 8-bromo-6-(piperidin-1-yl)-9H-purine (24). 
Spectrum 19. 
13
C NMR of 8-bromo-6-(piperidin-1-yl)-9H-purine (24). 
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Spectrum 20. 
13
C DEPT NMR of 8-bromo-6-(piperidin-1-yl)-9H-purine (24). 
Spectrum 21. COSY NMR of 8-bromo-6-(piperidin-1-yl)-9H-purine (24). 
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Spectrum 22. HSQC NMR of 8-bromo-6-(piperidin-1-yl)-9H-purine (24). 
Spectrum 23. HMBC NMR of 8-bromo-6-(piperidin-1-yl)-9H-purine (24). 
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9-Allyl-8-bromo-6-(piperidin-1-yl)-9H-purine (25) and 3-allyl-8-bromo-6-(piperidin-1-
yl)-3H-purine (26). 
 
Potassium carbonate (148 mg, 1.07 mmol) was added to a stirring solution of 8-bromo-6-
(piperidin-1-yl)-9H-purine 24 (100 mg, 0.361 mmol) in dry DMF (6 mL) at ambient 
temperature under N2-atm. After 20 min., allyl bromide (0.11 mL, 0.69 mmol) was added, the 
resulting mixture was stirred for 20 h., filtered and evaporated in vacuo. The isomers were 
separated by flash chromatography on silica gel using 0.5-2% MeOH / DCM as an eluent. 
This gave 24 mg (21%) of 9-allyl-8-bromo-6-(piperidin-1-yl)-9H-purine 25 as a colourless 
solid and 79 mg (69%) of 3-allyl-8-bromo-6-(piperidin-1-yl)-3H-purine 26 as a yellow solid. 
9-Allyl-8-bromo-6-(piperidin-1-yl)-9H-purine (25) 
1
H NMR (CDCl3, 400 MHz) δ 1.61-1.78 (m, 6H, 3 x CH2 in piperidine), 4.17 (brs, 4H, 2 x 
NCH2 in piperidine), 4.79 (d, J = 5.2 Hz, 2H, CH2 in allyl), 5.06 (d, J = 17.1 Hz, 1H, =CH2a in 
allyl), 5.23 (d, J = 10.5 Hz, 1H, =CH2b in allyl), 5.87-5.99 (m, 1H, =CH in allyl), 8.28 (s, 1H, 
H-2).  
 
13C NMR (CDCl3, 100 MHz) CH2 in piperidinyl)x CH2 in piperidinyl), 
 CH2 in allyl)x NCH2 in piperidinyl)CH2 in allyl)119.1 (C-5), 
(C-8), CH in allyl)C-4)C-2)C-6). 
 
MS (EI). m/z (rel. %): 323/321 (58/59, M
+
), 294 (22), 292 (22), 267 (15), 265 (15), 242 (100), 
214 (10), 187 (8), 159 (5), 84 (15).  
 
HRMS. Found 321.0583 calculated for C13H16N5Br 321.0589. 
 
M.p. 80-82 ºC (Lit.
23
 65-66 ºC). 
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Spectrum 24. 
1
H NMR of 9-allyl-8-bromo-6-(piperidin-1-yl)-9H-purine (25). 
 
Spectrum 25. 
13
C NMR of 9-allyl-8-bromo-6-(piperidin-1-yl)-9H-purine (25). 
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Spectrum 26. 
13
C DEPT NMR of 9-allyl-8-bromo-6-(piperidin-1-yl)-9H-purine (25). 
 
 
Spectrum 27. COSY NMR of 9-allyl-8-bromo-6-(piperidin-1-yl)-9H-purine (25). 
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Spectrum 28. HSQC NMR of 9-allyl-8-bromo-6-(piperidin-1-yl)-9H-purine (25). 
 
Spectrum 29. HMBC NMR of 9-allyl-8-bromo-6-(piperidin-1-yl)-9H-purine (25). 
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3-Allyl-8-bromo-6-(piperidin-1-yl)-3H-purine (26) 
 
1
H NMR (CDCl3, 400 MHz) δ 1.68-1.74 (m, 6H, 3 x CH2 in piperidinyl), 3.96 (brs, 2H, 
NCH2 in piperidinyl), 4.57 (brs, 2H, NCH2 in piperidinyl), 4.88 (d, J = 5.9 Hz, 2H, CH2 in 
allyl), 5.24-5.41 (m, 2H, =CH2 in allyl), 6.01-6.12 (m, 1H, =CH in allyl), 7.85 (s, 1H, H-2).  
 
13C NMR (CDCl3, 100 MHz) CH2 in piperidinyl)25.2(2x CH2 in piperidinyl), 44.6 
(CH2 in piperidinyl)CH2 in piperidinyl)CH2 in allyl)119.2 (CH2 in allyl), 
121.2 (C-5)CH in allyl)C-8)C-2)C-6)C-4). 
 
MS (EI). m/z (rel. %): 323/321 (72/74, M
+
), 294 (16), 292 (16), 282 (93), 280 (100), 254 (28), 
252 (29), 240 (15), 238 (15), 199 (12), 197 (11), 118 (5). 
 
HRMS. Found 321.0585 calculated for C13H16N5Br 321.0589. 
 
M.p. 111-113 ºC (Lit.
23
 82-83 ºC). 
 
 
Spectrum 30. 
1
H NMR of 3-allyl-8-bromo-6-(piperidin-1-yl)-3H-purine (26). 
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Spectrum 31. 
13
C NMR of 3-allyl-8-bromo-6-(piperidin-1-yl)-3H-purine (26). 
Spectrum 32. 
13
C DEPT NMR of 3-allyl-8-bromo-6-(piperidin-1-yl)-3H-purine (26). 
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Spectrum 33. COSY NMR of 3-allyl-8-bromo-6-(piperidin-1-yl)-3H-purine (26). 
Spectrum 34. HSQC NMR of 3-allyl-8-bromo-6-(piperidin-1-yl)-3H-purine (26). 
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Spectrum 35. HMBC NMR of 3-allyl-8-bromo-6-(piperidin-1-yl)-3H-purine (26). 
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6,8-Dichloro-9-ethyl-9H-purine (49) 
 
A solution of diisopropylamine (0.11 mL, 0.75 mmol) in dry THF (2 mL) was cooled to -78 
ºC under N2-atm. 1.03 M n-BuLi in hexane (0.68 mL, 0.70 mmol) was added dropwise over 
10 min. and the mixture was stirred at -78 ºC under N2-atm. for 1 h. 6-Chloro-9-ethyl-9H-
purine 27a (91 mg, 0.50 mmol) in dry THF (2 mL) was added dropwise over 10 min to the 
reaction mixture and stirred at -78ºC under N2-atm. for 1 h. C2Cl6 (237 mg, 1.00 mmol) was 
dissolved in dry THF (1 mL) and added dropwise over 10 min. to the reaction mixture and 
stirred at -78ºC under N2-atm. for 5 minutes. Sat. aq. NH4Cl (15 mL) was added and the 
mixture was left to warm up to r.t., and extracted with EtOAc (2 x 25 ml). The combined 
organic extracts were washed with brine (20 mL), dried (MgSO4) and evaporated in vacuo. 
The crude product was purified by flash chromatography eluting with 0-3% MeOH in DCM 
to give 81 mg (74%) of 6,8-dichloro-9-ethyl-9H-purine 49 as a yellow solid. 
 
1
H NMR (CDCl3, 400 MHz) δ 1.49 (t, J = 7.3 Hz, 3H, CH3), 4.38 (q, J = 7.3 Hz, 2H, CH2), 
8.73 (s, 1H, H-2).  
 
13
C NMR (CDCl3, 100 MHz) CH3)CH2), C-5)144.1 (C-8), 149.4 (C-
6)C-2)C-4) 
 
MS (EI). m/z (rel. %): 220/218 (5/31, M
+
), 216 (48), 192 (11), 190 (67), 188 (100), 155 (8), 
153(23), 127 (9). 
 
HRMS. Found 215.9963 calculated for C7H6N4Cl2 215.9970. 
M.p. 90-92 ºC (Lit.
21
 91.4-91.9 ºC). 
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Spectrum 36. 
1
H NMR of 6,8-dichloro-9-ethyl-9H-purine (49). 
 
Spectrum 37. 
13
C NMR of 6,8-dichloro-9-ethyl-9H-purine (49). 
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(Z)-6-(Piperidin-1-yl)-9-(prop-1-en-1-yl)-9H-purine (98) 
 
A solution of diisopropylamine (0.33 ml, 2.25 mmol) in dry THF (6 mL) was cooled to -78 ºC 
under N2-atm. 1.03 M n-BuLi in hexane (2.04 mL, 2.10 mmol) was added dropwise over 10 
min. and the mixture was stirred at -78 ºC under N2-atm. for 1 h. 9-Allyl-6-(piperidin-1-yl)-
9H-purine 33 (273 mg, 1.50 mmol) in dry THF (6 mL) was added dropwise over 10 min. to 
the reaction mixture and stirred at -78 ºC under N2-atm. for 1 h. Sat. aq. NH4Cl (45 mL) was 
added and the mixture was left to warm up to room temprature, and extracted with EtOAc (2 
x 75 mL). The combined organic extracts were washed with brine (60 mL), dried (MgSO4) 
and evaporated in vacuo. The products were separated by flash chromatography eluting with 
1:1 EtoAc:Hexane. This gave 101 mg (37%) of unaffected starting material 33 and 63 mg 
(23%) of (Z)-6-(piperidin-1-yl)-9-(prop-1-en-1-yl)-9H-purine 98 as a yellow oil. 
 
1
H NMR (CDCl3, 400 MHz) δ 1.58-1.76 (m, 6H, 3 x CH2 in piperidinyl), 1.80 (dd, J = 7.2, 
1.7 Hz, 3H, CH3), 4.22 (brs, 4H, 2 x NCH2 in piperidinyl), 5.72-5.82 (m, 1H, =CH in 
propenyl), 6.79 (dd, J = 8.6, 1.7 Hz, 1H, NCH= in propenyl), 7.80 (s, 1H, H-8), 8.31 (s, 1H, 
H-2).  
 
13C NMR (CDCl3, 100 MHz) CH3)CH2 in piperdinyl)x CH2 in 
piperdinylx NCH2 in piperdinyl119.0 (C-5), 120.5 (NCH= in propenyl), 122.5 
(=CH in propenyl)C-8)C-4)C-2), C-6). 
 
MS (EI). m/z (rel. %): 244/243 (18/100, M
+
), 228 (10), 214 (56), 200 (24), 188 (27), 160 (17), 
145 (15), 132 (5), 84 (15). 
 
HRMS. Found 243.1482 calculated for C13H17N5 243.1484. 
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Spectrum 38. 
1
H NMR of (Z)-6-(piperidin-1-yl)-9-(prop-1-en-1-yl)-9H-purine (98). 
Spectrum 39. 
13
C NMR of (Z)-6-(piperidin-1-yl)-9-(prop-1-en-1-yl)-9H-purine (98). 
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Spectrum 40. 
13
C DEPT NMR of (Z)-6-(piperidin-1-yl)-9-(prop-1-en-1-yl)-9H-purine (98). 
Spectrum 41. COSY NMR of (Z)-6-(piperidin-1-yl)-9-(prop-1-en-1-yl)-9H-purine (98). 
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Spectrum 42. HSQC NMR of (Z)-6-(piperidin-1-yl)-9-(prop-1-en-1-yl)-9H-purine (98). 
Spectrum 43. HMBC NMR of (Z)-6-(piperidin-1-yl)-9-(prop-1-en-1-yl)-9H-purine (98). 
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9-Allyl-8-chloro-6-(piperidin-1-yl)-9H-purine (96) and (Z)-8-chloro-6-(piperidin-1-yl)-9-
(prop-1-en-1-yl)-9H-purine (97) 
 
A solution of diisopropylamine (0.44 mL, 3.0 mmol) in dry THF (8 mL) was cooled to -78 ºC 
under N2-atm. 1.03 M n-BuLi in hexane (2.72 mL, 2.80 mmol) was added dropwise over 10 
min. and the mixture was stirred at -78ºC under N2-atm. for 1 h. 9-Allyl-6-(piperidin-1-yl)-
9H-purine 33 (364 mg, 2.00 mmol) in dry THF (8 mL) was added dropwise over 10 min. to 
the reaction mixture and stirred at -78 ºC under N2-atm. for 1 h. C2Cl6 (948 mg, 4.00 mmol) 
was dissolved in dry THF (4 mL) and added dropwise over 10 min to the reaction mixture and 
stirred at -78 ºC under N2-atm. for 5 min. Sat. aq. NH4Cl (60 mL) was added, the mixture was 
left to warm up to room temrature and extracted with EtOAc (2 x 100 mL). The combined 
organic extracts were washed with brine (80 mL), dried (MgSO4) and evaporated in vacuo. 
The products were separated by flash chromatography eluting with 15% EtoAc in hexane. 
This gave 130 mg (31%) of 9-allyl-8-chloro-6-(piperidin-1-yl)-9H-purine 96 as a colourless 
solid and 90 mg (22%) of (Z)-8-chloro-6-(piperidin-1-yl)-9-(prop-1-en-1-yl)-9H-purine 97 as 
a yellow solid. 
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9-Allyl-8-chloro-6-(piperidin-1-yl)-9H-purine (96) 
1
H NMR (CDCl3, 200 MHz) δ 1.56-1.69 (m, 6H, 3 x CH2 in piperidinyl), 4.16 (brs, 4H, 2x 
NCH2 in piperidinyl), 4.73 (dt, J = 5.3, 1.6 Hz, 2H, CH2 in allyl), 5.08 (d, J = 17.1, 1H, =CH2a 
in allyl), 5.18 (d, J = 10.4, 1H, =CH2b in allyl), 5.87-6.00 (m, 1H,=CH in allyl), 8.24 (s, 1H, 
H-2).  
13
C NMR (CDCl3, 100 MHz) δ 24.7 (CH2 in piperidinyl), 26.0 (2 x CH2 in piperidinyl), 45.0 
(CH2 in allyl), 46.3 (2 x NCH2 in piperdinyl), 118.1 (=CH2 in allyl), 118.5 (C-5), 130.8 (=CH 
in allyl), 135.4 (C-8), 151.6 (C-4), 152.5 (C-2), 152.6 (C-6). 
MS (EI). m/z (rel. %): 279/277 (33/100, M
+
), 262 (12), 248 (57), 236 (38), 222 (25), 208 (24), 
194 (21), 153 (9). 
HRMS. Found 277.1090 calculated for C7H6Cl2N4 277.1094. 
M.p. 81-83 ºC. 
 
 
Spectrum 44. 
1
H NMR of 9-allyl-8-chloro-6-(piperidin-1-yl)-9H-purine (96). 
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Spectrum 45. 
13
C NMR of 9-allyl-8-chloro-6-(piperidin-1-yl)-9H-purine (96). 
Spectrum 46. 
13
C DEPT NMR of 9-allyl-8-chloro-6-(piperidin-1-yl)-9H-purine (96). 
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Spectrum 47. COSY NMR of 9-allyl-8-chloro-6-(piperidin-1-yl)-9H-purine (96). 
Spectrum 48. HSQC NMR of 9-allyl-8-chloro-6-(piperidin-1-yl)-9H-purine (96). 
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Spectrum 49. HMBC NMR of 9-allyl-8-chloro-6-(piperidin-1-yl)-9H-purine (96). 
 
 
 
 
 
 
 
 
 
 
 
127 
 
(Z)-8-Chloro-6-(piperidin-1-yl)-9-(prop-1-en-1-yl)-9H-purine (97) 
1
H NMR (CDCl3, 400 MHz)  1.68 (dd, J = 7.0, 1.8 Hz, 3H, CH3), 1.66-1.77 (m, 6H, 3CH2 
in piperidinyl), 4.17 (brs, 4H, 2NCH2 in piperidinyl), 6.09-6.18 (m, 1H, =CH in propenyl), 
6.49 (dd, J = 8.0, 1.8 Hz, 1H, NCH= in propenyl), 8.30 (s, 1H, H-2). 
 
13
C NMR (CDCl3, 100 MHz)  13.2 (CH3), 24.7 (CH2 in piperidinyl), 26.1 (2CH2 in 
piperidinyl), 46.4 (2NCH2 in piperidinyl), 118.5 (=CH in propenyl), 119.5 (C-5), 131.4 
(NCH= in propenyl), 135.2 (C-8), 152.1 (C-4), 152.6 (C-2), 152.8 (C-6). 
 
MS (EI). m/z (rel. %): 279/277 (32/100, M
+
), 262 (11), 248 (59), 234 (21), 221 (27), 208 (14), 
194 (18), 179 (10). 
 
HRMS. Found 277.1091 calculated for C13H16N5Cl 277.1094. 
M.p. 69-71 ºC. 
 
 
Spectrum 50. 
1
H NMR of (Z)-8-chloro-6-(piperidin-1-yl)-9-(prop-1-en-1-yl)-9H-purine (97). 
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Spectrum 51. 
13
C NMR of (Z)-8-chloro-6-(piperidin-1-yl)-9-(prop-1-en-1-yl)-9H-purine (97). 
Spectrum 52. 
13
C DEPT NMR of (Z)-8-chloro-6-(piperidin-1-yl)-9-(prop-1-en-1-yl)-9H-purine (97). 
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Spectrum 53. COSY NMR of (Z)-8-chloro-6-(piperidin-1-yl)-9-(prop-1-en-1-yl)-9H-purine (97). 
Spectrum 54. HSQC NMR of (Z)-8-chloro-6-(piperidin-1-yl)-9-(prop-1-en-1-yl)-9H-purine (97). 
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Spectrum 55. HMBC NMR of (Z)-8-chloro-6-(piperidin-1-yl)-9-(prop-1-en-1-yl)-9H-purine (97). 
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8,9-Diallyl-6-(piperidin-1-yl)-9H-purine (71)
23
 
 
Allylmagnesium bromide (2.02 mL, 1.35 mmol, 0.67 M solution in diethyl ether) was added 
to a solution of compound 33 (109 mg, 0.448 mmol) in THF (5 mL) at 0 ºC under N2-atm and 
the resulting mixture was stirred at 0 ºC for 4 h. Sat. aq. NH4Cl (10 mL) was added, the 
phases were separated and the water layer was extracted with ethyl acetate (2  10 mL). The 
combined organic extracts were dried (MgSO4) and evaporated in vacuo. The product was 
purified by flash chromatography eluting with acetone-EtOAc-hexane (1:1:8) to give 113 mg 
(89%) of 8,9-diallyl-6-(piperidin-1-yl)-9H-purine 71 as a yellow oil. 
 
1
H NMR (CDCl3, 400 MHz)  1.55-1.75 (m, 6H, 3CH2 in piperidinyl), 3.56 (d, J = 6.2, 2H, 
C(8)CH2), 4.18 (brs, 4H, 2NCH2 in piperidinyl), 4.72 (d, J = 5.0, 2H, N(9)CH2), 4.89 (d, J = 
17.2 Hz, 1H, =CH2a  in C(8) allyl), 5.04-5.22 (m, 3H, =CH2b in C(8) allyl and =CH2 in N(9) 
allyl), 5.80-6.07 (m, 2H, 2CH= in C(8) allyl and N(9) allyl), 8.25 (s, 1H, H-2). 
 
13C NMR (CDCl3, 100 MHz) 24.8 (CH2 in piperidinyl), 26.0 (2CH2 in piperidinyl), 32.41 
(C(8)CH2), 44.17 (N(9)CH2), 46.29 (2NCH2 in piperidinyl), 116.99 (=CH2 in C(8) allyl), 
117.67 (=CH2 in N(9) allyl), 118.88 (C-5), 132.19 (CH= in N(9) allyl), 132.58 (CH= in C(8) 
allyl), 147.67 (C-8), 151.81 (C-4), 151.84 (C-2), 153.31 (C-6). 
 
MS (EI). m/z (rel. %): 284/283 (21/100, M
+
), 254 (38), 242 (37), 227 (33), 214 (22), 200 (18), 
187 (10), 159 (9).  
HRMS. Found 283.1792 calculated for C16H21N5 283.1797. 
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Spectrum 56. 
1
H NMR of 8,9-diallyl-6-(piperidin-1-yl)-9H-purine (71). 
Spectrum 57. 
13
C NMR of 8,9-diallyl-6-(piperidin-1-yl)-9H-purine (71). 
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4-(Piperidin-1-yl)-6,9-dihydropyrido[1,2-e]purine (74) 
 
Grubbs’ 2nd generation catalyst [26 mg (in 4 parts each after 2 h), 0.030 mmol] was added to a 
solution of compound 71 ( 45 mg, 0.15 mmol) in dry DCM (25 mL) after removing the air by 
a pump and filling with argon (three cycles) and the solution was stirred at room temprature 
for 48 h. After the evaporation of the solvent the residue was purified by column 
chromatography [silica gel, hexane – ethyl acetate (2:1)] to give 38 mg (94%) of 4-(piperidin-
1-yl)-6,9-dihydropyrido[1,2-e]purine 74 as a yellow solid. 
 
1
H NMR (CDCl3, 400 MHz) δ 1.55-1.75 (m, 6H, 3CH2 in piperidine), 3.54-3.65 (m, 2H, 
C(8)CH2), 4.18 (brs, 4H, 2NCH2 in piperidine), 4.63-4.71 (m, 2H, N(9)CH2), 5.94-6.08 (m, 
2H, CH=CH), 8.32 (s, 1H, H-2).  
 
13C NMR (CDCl3, 100 MHz) CH2 in piperdine)C(8)CH2), 26.1 (2 CH2 in 
piperidine)N(9)CH2) (NCH2 in piperdine) (C-5), 119.9 (CH=), 122.1 
CH=)C-8)C-4)C-2), C-6). 
 
MS (EI). m/z (rel. %): 256/255 (15/100, M
+
), 226 (51), 212 (27), 200 (27), 199 (34), 187 (15), 
172 (19), 145 (17), 84 (9).  
HRMS. Found 255.1480 calculated for C14H17N5 255.1484. 
M.p. 110-112 ºC (Lit.
23
 113-115 ºC). 
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Spectrum 58. 
1
H NMR of 4-(piperidin-1-yl)-6,9-dihydropyrido[1,2-e]purine (74). 
Spectrum 59. 
13
C NMR of 4-(piperidin-1-yl)-6,9-dihydropyrido[1,2-e]purine (74). 
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4-(Piperidin-1-yl)pyrido[1,2-e]purine (7) 
 
DDQ (209 mg, 0.920 mmol) was added to a solution of compound 74 (117 mg, 0.460 mmol) 
in dry DCM (40 mL) at room temperature and the resulting mixture was stirred for 24 h and 
evaporated in vacuo. The product was purified by flash chromatography on silica gel eluting 
with EtOAc-hexane (1:1) to give 102 mg (87%) of 4-(piperidin-1-yl)pyrido[1,2-e]purine 7 as 
a colourless solid. 
 
1
H NMR (CDCl3, 400 MHz) δ 1.67-1.81 (m, 6H, 3CH2), 4.20-4.52 (s, 4H, 2NCH2), 6.83-
6.89 (m, 1H, N(9)CH=CH), 7.34-7.40 (m, 1H, C(8)CH=CH), 7.61 (d, J = 9.3 Hz, 1H, 
C(8)CH), 8.43 (s, 1H, H-2), 8.57 (d, J = 6.7 Hz, 1H, N(9)CH). 
 
13C NMR (CDCl3, 100 MHz) δ 24.8 (CH2), 26.2 (2CH2), 46.7 (2NCH2), 111.4 
(N(9)CH=CH), 118.3 (C(8)CH), 122.1 (C-5), 124.1 (N(9)CH), 129.2 (C(8)CH=CH), 143.9 
(C-8), 144.7 (C-4), 150.3 (C-2), 154.2 (C-6). 
 
MS (EI). m/z (rel. %): 254/253 (17/100, M
+
), 224 (35), 210 (32), 198 (22), 197 (34), 185 (21), 
170 (23), 143 (34), 84 (11), 78 (22).  
HRMS. Found 253.1322 calculated for C14H15N5 253.1327. 
M.p. 125-127 
o
C (Lit.
1
 124-126 
o
C). 
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Spectrum 60. 
1
H NMR of 4-(piperidin-1-yl)pyrido[1,2-e]purine (7). 
Spectrum 61. 
13
C NMR of 4-(piperidin-1-yl)pyrido[1,2-e]purine (7). 
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8,9-Diallyl-6-chloro-9H-purine (100a) and 8,9-diallyl-6-chloro-8,9-dihydro-7H-purine 
(100b) 
Method A: 
 
Allylmagnesium bromide (1.42 mL, 0.95 mmol of 0.67 M solution in diethyl ether) was 
added to a solution of compound 19 (88 mg, 0.45 mmol) in THF (5 mL) at 0 ºC under N2-atm, 
and the resulting mixture was stirred at 0 ºC for 20 min. Sat. aq. NH4Cl (10 mL) was added, 
the phases were separated and the water layer was extracted with ethyl acetate (2  10 mL). 
The combined organic extracts were dried (MgSO4) and evaporated in vacuo. The products 
were isloated by flash chromatography on silica gel eluting with acetone-EtOAc-hexane 
(1:1:8) to afford 11 mg (10%) of 8,9-diallyl-6-chloro-9H-purine 100a as a yellow oil and 237 
mg (74%) of 8,9-diallyl-6-chloro-8,9-dihydro-7H-purine 100b as a yellow oil. 
8,9-Diallyl-6-chloro-9H-purine (100a) 
1
H NMR (CDCl3, 400 MHz) 3.69 (d, J = 6.2, 2H, C(8)CH2), 4.83 (d, J = 5.3, 2H, N(9)CH2), 
4.96 (d, J = 17.1 Hz, 1H, =CH2a in C(8) allyl), 5.15 (d, J = 17.1 Hz, 1H, =CH2a in N(9) allyl) 
5.21 (d, J = 10.2 Hz, 2H, =CH2b in N(9) allyl and =CH2b in C(8) allyl), 5.84-6.06 (m, 2H, 
2CH=), 8.60 (s, 1H, H-2). 
13C NMR (CDCl3, 100 MHz) δ 32.7 (C(8)CH2), 44.9 (N(9)CH2), 118.2 (=CH2 in C(8) allyl), 
119.1 (=CH2 in N(9) allyl), 130.8 (C-5), 130.9 (CH= in N(9) allyl), 131.0 (CH= in C(8) allyl), 
149.2 (C-4), 151.3 (C-2), 152.9 (C-6), 156.1 (C-8). 
MS (EI). m/z (rel. %): 236/234 (24/73, M
+
), 233 (100), 219 (9), 207 (21), 193 (43), 168 (6), 
157 (12).  
HRMS. Found 234.0672 calculated for C11H11N4Cl 234.0672 
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Spectrum 62. 
1
H NMR of 8,9-diallyl-6-chloro-9H-purine (100a). 
Spectrum 63. 
13
C NMR of 8,9-diallyl-6-chloro-9H-purine (100a). 
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Spectrum 64. 
13
C DEPT NMR of 8,9-diallyl-6-chloro-9H-purine (100a). 
Spectrum 65. 
13
C APT NMR of 8,9-diallyl-6-chloro-9H-purine (100a). 
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Spectrum 66. COSY NMR of 8,9-diallyl-6-chloro-9H-purine (100a). 
Spectrum 67. HSQC NMR of 8,9-diallyl-6-chloro-9H-purine (100a). 
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Spectrum 68. HMBC NMR of 8,9-diallyl-6-chloro-9H-purine (100a). 
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8,9-Diallyl-6-chloro-8,9-dihydro-7H-purine (100b) 
1
H NMR (CDCl3, 400 MHz) δ 2.39-2.47 (m, 1H, C(8)CH2a), 2.56-2.63 (m, 1H, C(8)CH2b), 
3.80 (ddt, J = 16.1, 6.9, 1.3 Hz, 1H, NCH2a), 4.26 (ddt, J = 16.1, 4.9, 1.7 Hz, 1H, NCH2b), 
4.31 (brs, 1H, NH), 5.14-5.31 (m, 4H, 2CH2=), 5.40 (dt, J = 6.7, 2.6 Hz, 1H, H-8), 5.67-5.86 
(m, 2H, 2CH=), 7.81 (s, 1H, H-2). 
13C NMR (CDCl3, 100 MHz) δ 39.7 (CH2), 44.6 (NCH2), 76.1 (C-8), 118.6 (=CH2 in N(9) 
allyl), 120.4 (=CH2 in C(8) allyl), 127.8 (C-6), 129.3 (C-5), 130.5 (CH= in C(8) allyl), 131.6 
(CH= in N(9) allyl), 149.5 (C-2), 159.1 (C-4). 
MS (EI). m/z (rel. %): 238/236 (21/6, M
+
), 237 (100), 201 (14), 195 (59), 160 (7). 
MS (ESI). 237.0901 [M+H]
+
 calculated for C11H13N4Cl 237.0829. 
 
 
 
Spectrum 69. 
1
H NMR of 8,9-diallyl-6-chloro-8,9-dihydro-7H-purine (100b). 
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Spectrum 70. 
13
C NMR of 8,9-diallyl-6-chloro-8,9-dihydro-7H-purine (100b). 
Spectrum 71. 
13
C DEPT NMR of 8,9-diallyl-6-chloro-8,9-dihydro-7H-purine (100b). 
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Spectrum 72. COSY NMR of 8,9-diallyl-6-chloro-8,9-dihydro-7H-purine (100b). 
Spectrum 73. HSQC NMR of 8,9-diallyl-6-chloro-8,9-dihydro-7H-purine (100b). 
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Spectrum 74. HMBC NMR of 8,9-diallyl-6-chloro-8,9-dihydro-7H-purine (100b). 
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Method B: 
Allylmagnesium bromide (1.42 mL, 0.951 mmol of 0.67 M solution in diethyl ether) was 
added to a solution of compound 19 (88 mg, 0.45 mmol) in THF (5 mL) at 0 ºC under N2-atm, 
and the resulting mixture was stirred at 0 ºC for 20 min. Sat. aq. NH4Cl (10 mL) was added, 
the phases were separated and the water layer was extracted with ethyl acetate (2  10 mL). 
The combined organic extracts were dried (MgSO4) and evaporated in vacuo. The crude 
product was dissolved in dry DCM (3 mL), MnO2 (196 mg, 2.25 mmol) was added and the 
mixture was stirred at r.t. for 2 h and evaporated in vacuo. The product was purified by flash 
chromatography on silica gel eluting with acetone-EtOAc-hexane (1:1:8) to give 76 mg (73%) 
of 8,9-diallyl-6-chloro-9H-purine 100a as a yellow oil.  
 
Method C:  
Compound 19 (292 mg, 1.50 mmol) and indium powder (1.378 g, 12.00 mmol) were stirred in 
dry THF (9 mL). Allyl bromide (1.56 mL, 18.034 mmol) was added and the reaction was 
stirred at room temperature, saturated aqueous solution of NH4Cl (18 mL) was added, the 
phases were separated and the water layer was extracted with ethyl acetate (2  18 mL). The 
combined organic extracts were dried (MgSO4) and evaporated in vacuo. The crude product 
was dissolved in dry DCM (9 mL), MnO2 (653 mg, 7.50 mmol) was added and the resulting 
mixture was stirred at room tepmerature for 2 h. The crude product was purified by flash 
chromatography on silica gel eluting with EtOAc-hexane (1:1) to give 170 mg (48%) of 8,9-
diallyl-6-chloro-9H-purine 100a as a yellow oil. 
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4-Chloro-6,9-dihydropyrido[1,2-e]purine (107). 
 
 
Grubbs’ 2nd generation catalyst (63 mg, 0.074 mmol) was added to a solution of compound 
100a (218 mg, 0.920 mmol) in dry DCE (50 mL) after removing the air by a pump and filling 
with argon (three cycles) and the solution was refluxed for 48 h. After evaporation of the 
solvent in vacuo the residue was purified by flash chromatography eluting with EtOAc-
hexane (1:1) to give 187 mg (97%) of 4-chloro-6,9-dihydropyrido[1,2-e]purine 107 as a 
colourless solid. 
 
 
1
H NMR (CDCl3, 400 MHz) δ 3.76-3.80 (m, 2H, C(8)CH2), 4.78-4.87 (m, 2H, NCH2), 6.18-
6.04 (m, 2H, CH=CH), 8.69 (s, 1H, H-2). 
 
13
C NMR (CDCl3, 100 MHz) δ 25.8 (C(8)CH2), 42.6 (NCH2), 119.4 (CH=), 121.7 (CH=), 
131.2 (C-5), 149.1 (C-6), 151.0 (C-2), 151.9 (C-4), 152.1 (C-8). 
 
MS (EI). m/z (rel. %) 208/206 (38/100, M
+
), 207 (31), 205 (54), 169 (32), 153 (11), 155 (4), 
85 (5), 78 (8).  
 
HRMS. Found 206.0362 calculated for C9 H7N4Cl 206.0359. 
 
M.p. 160-162 ºC 
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Spectrum 75. 
1
H NMR of 4-chloro-6,9-dihydropyrido[1,2-e]purine (107). 
 
 
Spectrum 76. 
13
C NMR of 4-chloro-6,9-dihydropyrido[1,2-e]purine (107). 
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Spectrum 77. 
13
C DEPT NMR of 4-chloro-6,9-dihydropyrido[1,2-e]purine (107). 
 
 
Spectrum 78. COSY NMR of 4-chloro-6,9-dihydropyrido[1,2-e]purine (107). 
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Spectrum 79. HSQC NMR of 4-chloro-6,9-dihydropyrido[1,2-e]purine (107). 
 
Spectrum 80. HMBC NMR of 4-chloro-6,9-dihydropyrido[1,2-e]purine (107). 
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4-Chloropyrido[1,2-e]purine (9)  
 
 
 
DDQ (411 mg, 1.80 mmol) was added to a solution of compound 107 (187 mg, 0.900 mmol) 
in dry DCE (45 mL) and the resulting mixture was refluxed for 24 h. After evaporation of the 
solvent in vacuo the residue was purified by flash chromatography on silica gel eluting with 
EtOAc-hexane (1:1) to give 170 mg (91%) of 4-chloropyrido[1,2-e]purine 9 as a colourless 
solid. 
 
1
H NMR (CDCl3, 400 MHz) δ 7.02-7.09 (m, 1H, NCH=CH), 7.62-7.69 (m, 1H, 
C(8)CH=CH), 7.80 (d, J = 9.3 Hz, 1H, C(8)CH), 8.74 (d, J = 6.8 Hz, 1H, NCH), 8.85 (s, 1H, 
H-2). 
 
13
C NMR (CDCl3, 100 MHz) δ 112.8 (NCH=CH), 119.0 (C(8)CH), 125.1(NCH), 132.74 (C-
5), 133.2 (C(8)CH=CH), 146.3 (C-4), 149.0 (C-8), 149.1 (C-2), 151.0 (C-6). 
 
MS (EI). m/z (rel. %): 206/204 (35/100, M
+
), 179 (2), 177 (7), 169 (41), 142 (5), 78 (20).  
HRMS. Found 204.0201 calculated for C9H5N4Cl 204.0203. 
M.p. 247-249 
o
C (Lit.
1
 250 
o
C). 
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Spectrum 81. 
1
H NMR of 4-chloropyrido[1,2-e]purine (9).  
 
Spectrum 82. 
13
C NMR of 4-chloropyrido[1,2-e]purine (9).  
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7,8-Diallyl-6-(piperidin-1-yl)-7H-purine (103) 
 
 
Allylmagnesium bromide (3.67 mL, 2.458 mmol of 0.67 M solution in diethylether) was 
added to a solution of compound 95 (300 mg, 1.23 mmol) in THF (15mL) at 0 ºC under N2-
atm, and the resulted mixture was stirred at 0 ºC for 40 min. Sat. aq. NH4Cl (30 mL) was 
added, the phases were separated and the water layer was extracted with ethyl acetate (2x30 
mL). The combined organic extracts were dried (MgSO4) and evaporated in vacuo. The crude 
product was dissolved in dry DCM (60 mL), MnO2 (535 mg, 6.15 mmol) was added and the 
mixture was stirred at room temperature for 2 h and evaporated in vacuo. The crude product 
was purified by flash chromatography on silica gel eluting with EtOAc-hexane (1:1) to give 
296 mg (85%) of 7,8-diallyl-6-(piperidin-1-yl)-7H-purine 103 as a yellow oil. 
1
H NMR (CDCl3, 400 MHz) δ
 
1.44-1.63 (m, 6H, 3CH2 in piperidinyl), 3.02-3.17 (m, 4H, 
2NCH2 in piperidinyl), 3.52 (dt, J = 6.4, 1.6 Hz, 2H, C(8)CH2), 4.76-4.87 (m, 3H, N(7)CH2 
and =CH2a in N(7) allyl), 4.97-5.08 (m, 2H, =CH2 in C(8) allyl), 5.13 (d, J = 10.5 Hz, 1H, 
=CH2b in N(7) allyl), 5.76-5.99 (m, 2H, =CH in N(7) allyl and =CH in C(8) allyl), 8.48 (s, 1H, 
H-2). 
 
 
13
C NMR (CDCl3, 100 MHz) δ 24.0 (CH2 in piperidinyl), 25.4 (2CH2 in piperidinyl), 32.4 
(C(8)CH2), 46.6 (N(7)CH2), 51.2 (2NCH2 in piperidinyl), 116.9 (C-5), 117.3 (=CH2 in N(7) 
allyl), 118.1 (=CH2 in C(8) allyl), 131.7 (=CH in C(8) allyl), 132.3 (=CH in N(7) allyl), 151.9 
(C-2), 155.5 (C-6), 157.4 (C-8), 160.5 (C-4).  
 
MS (EI). m/z (rel. %): 284/283 (26/94, M
+
), 268 (47), 254 (58), 242 (65), 240 (24), 227 (18), 
200 (95), 199 (97), 174 (26), 84 (100). 
HRMS. Found 283.1789 calculated for C16H21N5 283.1797. 
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Spectrum 83. 
1
H NMR of 7,8-diallyl-6-(piperidin-1-yl)-7H-purine (103). 
 
Spectrum 84. 
13
C NMR of 7,8-diallyl-6-(piperidin-1-yl)-7H-purine (103). 
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Spectrum 85. 
13
C DEPT NMR of 7,8-diallyl-6-(piperidin-1-yl)-7H-purine (103). 
 
Spectrum 86. HSQC NMR of 7,8-diallyl-6-(piperidin-1-yl)-7H-purine (103). 
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Spectrum 87. HMBC NMR of 7,8-diallyl-6-(piperidin-1-yl)-7H-purine (103). 
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8-Allyl-6-chloro-7-methyl-7H-purine (106a), (E)-6-chloro-7-methyl-8-(prop-1-en-1-yl)-
7H-purine (106b), and (E)-3-(6-chloro-7-methyl-7H-purin-8-yl)acrylaldehyde (106c). 
 
Allylmagnesium bromide (3.52 mL, 2.358 mmol of 0.67 M solution in diethyl ether) was 
added to a solution of compound 18 (200 mg, 1.18 mmol) in THF (15 mL) at -20 ºC (1:3 
NaCl/ice bath) under N2-atm, and the resulting mixture was stirred at this temperature for 20 
min. Sat. aq. NH4Cl (30 mL) was added, the phases were separated and the water layer was 
extracted with ethyl acetate (2  30 mL). The combined organic extracts were dried (MgSO4) 
and the solvent was evaporated in vacuo. The crude product was dissolved in dry DCM (60 
mL), MnO2 (513 mg, 5.90 mmol) was added and the mixture was stirred at room temperature 
for 2 h. MnO2 was filtered off, and the solvent was evaporated in vacuo. The crude product 
was purified by flash chromatography on silica gel eluting with EtOAc-hexane (1:1) to give 
216 mg of a yellow oil composed of a mixture of 8-allyl-6-chloro-7-methyl-7H-purine 106a 
(85%), (E)-6-chloro-7-methyl-8-(prop-1-en-1-yl)-7H-purine 106b (9%), and (E)-3-(6-chloro-
7-methyl-7H-purin-8-yl)acrylaldehyde 106c (6%). 
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8-Allyl-6-chloro-7-methyl-7H-purine (106a) 
1
H NMR (CDCl3, 400 MHz) δ
 
3.78 (d, J = 6.3 Hz, 2H, CH2), 4.05 (s, 3H, CH3), 5.11 (dd, J = 
17.2, 1.3 Hz, 1H, =CH2a), 5.20 (dd, J = 10.2, 1.3 Hz, 1H, =CH2b), 5.98-6.12 (m, 1H, CH=), 
8.79 (s, 1H, H-2). 
13
C NMR (CDCl3, 100 MHz) δ 32.4 (CH3), 32.5 (CH2), 119.2 (=CH2), 123.7 (C-5), 130.5 
(=CH), 141.8 (C-6), 152.1 (C-2), 159.8 (C-8), 161.0 (C-4). 
 
MS (EI). m/z (rel. %): 210/208 (20/60, M
+
), 207 (100), 193 (11), 182 (11), 167 (9), 100 (11), 
79 (5). 
 
MS (ESI). 209.0618 [M+H]
+
 calculated for C9H9N4Cl 209.0516. 
 
(E)-6-Chloro-7-methyl-8-(prop-1-en-1-yl)-7H-purine (106b) 
1
H NMR (CDCl3, 400 MHz) δ
 
2.07 (d, J = 7.0 Hz, 1H, CH3 in C(8) propenyl), 4.08 (s, 3H, 
NCH3), 6.50 (d, J = 15.5 Hz, 1H, C(8)CH), 7.45 (m, 1H, C(8)CH=CH), 8.75 (s, 1H, H-2). 
  
13
C NMR (CDCl3, 100 MHz) δ 19.3 (CH3 in C(8) propenyl), 31.9 (NCH3), 115.4 (C(8)CH), 
123.6 (C-5), 141.6 (C-6), 143.9 (C(8)CH=CH), 152.3 (C-2), 157.2 (C-8), 161.0 (C-4). 
MS (EI). m/z (rel. %): 210/208 (20/60, M
+
), 207 (100), 195 (24), 193 (70), 182 (7), 167 (8), 
100 (14), 79 (6). 
MS (ESI). 209.0618 [M+H]
+
 calculated for C9H9N4Cl 209.0516. 
 
(E)-3-(6-Chloro-7-methyl-7H-purin-8-yl)acrylaldehyde (106c) 
 
1
H NMR (CDCl3, 400 MHz) δ 4.00 (s, 1H, CH3), 7.42 (dd, J = 15.5, 7.0 Hz, 1H, 
C(8)CH=CH), 7.59 (d, J = 15.5 Hz, 1H, C(8)CH), 8.74 (s, 1H, H-2), 9.81 (d, J = 7.0 Hz, 1H, 
CHO). 
13
C NMR (CDCl3, 100 MHz) δ 32.7 (CH3), 124.4 (C-5), 132.0 (C(8)CH), 138.2 
(C(8)CH=CH), 143.4(C-6), 152.9 (C-2), 153.6 (C-8), 163.4 (C-4), 191.6 (CHO). 
MS (EI). m/z (rel. %): 224/222 (5/16, M
+
), 208 (58), 207 (100), 195 (24), 193 (70), 182 (7), 
167 (8), 100 (14), 79 (6). 
MS (ESI). 223.0412 [M+H]
+
 calculated for C9H7N4OCl 223.0308. 
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Spectrum 88. 
1
H NMR of a mixture of 8-allyl-6-chloro-7-methyl-7H-purine (106a), (E)-6-chloro-7-methyl-8-
(prop-1-en-1-yl)-7H-purine (106b), and (E)-3-(6-chloro-7-methyl-7H-purin-8-yl)acrylaldehyde (106c). 
Spectrum 89. 
13
C NMR of a mixture of 8-allyl-6-chloro-7-methyl-7H-purine (106a), (E)-6-chloro-7-methyl-8-
(prop-1-en-1-yl)-7H-purine (106b), and (E)-3-(6-chloro-7-methyl-7H-purin-8-yl)acrylaldehyde (106c). 
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Spectrum 90. 
13
C DEPT NMR of a mixture of 8-allyl-6-chloro-7-methyl-7H-purine (106a), (E)-6-chloro-7-
methyl-8-(prop-1-en-1-yl)-7H-purine (106b), and (E)-3-(6-chloro-7-methyl-7H-purin-8-yl)acrylaldehyde (106c). 
Spectrum 91. 
13
C APT NMR of a mixture of 8-allyl-6-chloro-7-methyl-7H-purine (106a), (E)-6-chloro-7-
methyl-8-(prop-1-en-1-yl)-7H-purine (106b), and (E)-3-(6-chloro-7-methyl-7H-purin-8-yl)acrylaldehyde (106c). 
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Spectrum 92. COSY NMR of a mixture of 8-allyl-6-chloro-7-methyl-7H-purine (106a), (E)-6-chloro-7-methyl-
8-(prop-1-en-1-yl)-7H-purine (106b), and (E)-3-(6-chloro-7-methyl-7H-purin-8-yl)acrylaldehyde (106c). 
Spectrum 93. HSQC NMR of a mixture of 8-allyl-6-chloro-7-methyl-7H-purine (106a), (E)-6-chloro-7-methyl-
8-(prop-1-en-1-yl)-7H-purine (106b), and (E)-3-(6-chloro-7-methyl-7H-purin-8-yl)acrylaldehyde (106c). 
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Spectrum 94. HMBC NMR of a mixture of 8-allyl-6-chloro-7-methyl-7H-purine (106a), (E)-6-chloro-7-methyl-
8-(prop-1-en-1-yl)-7H-purine (106b), and (E)-3-(6-chloro-7-methyl-7H-purin-8-yl)acrylaldehyde (106c). 
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7,8-Diallyl-6-chloro-7H-purine (105a), (E)-7-allyl-6-chloro-8-(prop-1-en-1-yl)-7H-purine 
(105b), and (E)-3-(7-allyl-6-chloro-7H-purin-8-yl)acrylaldehyde (105c). 
 
 
 
Allylmagnesium bromide (3.06 mL, 2.04 mmol of 0.67 M solution in diethylether) was added 
to a solution of compound 20 (200 mg, 1.02 mmol) in THF (10 mL) at -20 ºC (1:3 NaCl/ice 
bath) under N2-atm, and the resulting mixture was stirred at this temperature for 5 min. Sat. 
aq. NH4Cl (20 mL) was added, the phases were separated and the water layer was extracted 
with ethyl acetate (2  20 mL). The combined organic extracts were dried (MgSO4) and the 
solvent was evaporated in vacuo. The crude product was dissolved in dry DCM (40 mL), 
MnO2 (447 mg, 5.10 mmol) was added and the mixture was stirred at room temperature for 2 
h. MnO2 was filtered off, and the solvent was evaporated in vacuo. The crude product was 
purified by flash chromatography on silica gel eluting with EtOAc-hexane (1:1) to give 195 
mg of a yellow oil composed of a mixture of 7,8-diallyl-6-chloro-7H-purine 105a (72%), (E)-
7-allyl-6-chloro-8-(prop-1-en-1-yl)-7H-purine 105b (20%), and (E)-3-(7-allyl-6-chloro-7H-
purin-8-yl) acrylald- ehyde 105c (8%). 
7,8-Diallyl-6-chloro-7H-purine (105a) 
1
H NMR (CDCl3, 400 MHz) δ
 
3.72 (dt, J = 6.4, 1.6 Hz, 1H, C(8)CH2), 4.85 (dt, J = 17.1, 1.8 
Hz, 1H, =CH2a in N(7) allyl), 5.07 (dt, J = 4.7, 1.8 Hz, 1H, NCH2), 5.18-5.30 (m, 3H, =CH2 in 
C(8) allyl and =CH2b in N(7) allyl), 5.94-6.14 (m, 2H, CH= in C(8) allyl and CH= in N(7) 
allyl), 8.80 (s, 1H, H-2). 
 
13
C NMR (CDCl3, 100 MHz) δ 32.3 (C(8)CH2), 47.0 (NCH2), 117.8 (=CH2 in N(7) allyl), 
119.2 (=CH2 in C(8) allyl), 123.2 (C-6), 130.7 (CH= in C(8) allyl), 131.8 (CH= in N(7) allyl), 
141.7 (C-4), 152.2 (C-2), 160.0 (C-8), 161.1 (C-5).  
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MS (EI). m/z (rel. %): 236/234 (31/90, M
+
), 233 (100), 219 (18), 207 (20), 168 (6), 157 (24), 
130 (7), 103 (5). 
MS (ESI). 235.0751 [M+H]
+
 calculated for C11H11N4Cl 235.0672. 
 
(E)-7-Allyl-6-chloro-8-(prop-1-en-1-yl)-7H-purine (105b) 
1
H NMR (CDCl3, 400 MHz) δ
 
2.05 (dd, J = 7.0, 1.8 Hz, 1H, CH3), 5.01-5.04 (m, 1H, NCH2), 
5.07-5.11 (m, 2H, =CH2), 5.98-6.01 (m, 1H, CH= in N(7) allyl), 6.41 (dd, J = 15.2, 1.8 Hz, 
1H, C(8)CH), 7.40-7.53 (m, 1H, C(8)CH=CH), 8.76 (s, 1H, H-2). 
 
13
C NMR (CDCl3, 100 MHz) δ 19.3 (CH3), 46.5 (NCH2), 115.4 (C(8)CH), 117.5 (=CH2 in 
N(7) allyl), 123.0 (C-6), 144.1 (C(8)CH=CH), 131.8 (CH= in N(7) allyl), 141.4 (C-4), 
152.3(C-2), 157.2 (C-8), 161.3 (C-5). 
MS (EI). m/z (rel. %): 236/234 (30/90, M
+
), 233 (100), 219 (18), 195 (26), 193 (80), 157 (24), 
130 (6), 103 (5). 
MS (ESI). 235.0751 [M+H]
+
 calculated for C11H11N4Cl 235.0672. 
 
(E)-3-(7-Allyl-6-chloro-7H-purin-8-yl)acrylaldehyde (105c) 
1
H NMR (CDCl3, 400 MHz) δ
 
4.84 (dt, J = 12.3, 2.0 Hz, 2H, NCH2), 5.24 (dt, J = 10.5, 1.8 
Hz, 2H, =CH2), 6.01-6.06 (m, 2H, CH= in N(7) allyl), 7.42 (dd, J = 15.5, 6.8 Hz, 1H, 
C(8)CH=CH), 7.50 (d, J = 15.5 Hz, 1H, C(8)CH), 8.76 (s, 1H, H-2), 9.77 (d, J = 6.8 Hz, 1H, 
CHO). 
 
13
C NMR (CDCl3, 100 MHz) δ 47.1 (NCH2), 118.1 (=CH2), 132.2 (CH= in N(7) allyl), 138.3 
(C(8)CH=CH), 141.4 (C-6), 151.3 (C(8)CH), 153.7 (C-8), 157.1 (C-2), 160.5 (C-4), 161.1 (C-
5), 191.6 (CHO). 
MS (EI). m/z (rel. %): 250/248 (10/33, M
+
), 234 (80), 219 (100), 205 (41), 193 (75), 157 (24), 
130 (6). 
MS (ESI). 249.0672 [M+H]
+
 calculated for C11H11N4Cl 249.0465. 
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Spectrum 95. 
1
H NMR of a mixture of 7,8-diallyl-6-chloro-7H-purine (105a), (E)-7-allyl-6-chloro-8-(prop-1-
en-1-yl)-7H-purine (105b), and (E)-3-(7-allyl-6-chloro-7H-purin-8-yl)acrylaldehyde (105c). 
Spectrum 96. 
13
C NMR of a mixture of 7,8-diallyl-6-chloro-7H-purine (105a), (E)-7-allyl-6-chloro-8-(prop-1-en-1-
yl)-7H-purine (105b), and (E)-3-(7-allyl-6-chloro-7H-purin-8-yl)acrylaldehyde (105c). 
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Spectrum 97. 
13
C DEPT NMR of a mixture of 7,8-diallyl-6-chloro-7H-purine (105a), (E)-7-allyl-6-chloro-8-
(prop-1-en-1-yl)-7H-purine (105b), and (E)-3-(7-allyl-6-chloro-7H-purin-8-yl)acrylaldehyde (105c). 
Spectrum 98. 
13
C APT NMR of a mixture of 7,8-diallyl-6-chloro-7H-purine (105a), (E)-7-allyl-6-chloro-8-
(prop-1-en-1-yl)-7H-purine (105b), and (E)-3-(7-allyl-6-chloro-7H-purin-8-yl)acrylaldehyde (105c). 
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Spectrum 99. COSY NMR of a mixture of 7,8-diallyl-6-chloro-7H-purine (105a), (E)-7-allyl-6-chloro-8-(prop-
1-en-1-yl)-7H-purine (105b), and (E)-3-(7-allyl-6-chloro-7H-purin-8-yl)acrylaldehyde (105c). 
Spectrum 100. HSQC NMR of a mixture of 7,8-diallyl-6-chloro-7H-purine (105a), (E)-7-allyl-6-chloro-8-
(prop-1-en-1-yl)-7H-purine (105b), and (E)-3-(7-allyl-6-chloro-7H-purin-8-yl)acrylaldehyde (105c). 
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Spectrum 101. HMBC NMR of a mixture of 7,8-diallyl-6-chloro-7H-purine (105a), (E)-7-allyl-6-chloro-8-
(prop-1-en-1-yl)-7H-purine (105b), and (E)-3-(7-allyl-6-chloro-7H-purin-8-yl)acrylaldehyde (105c). 
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